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Overview {#bph14751-sec-003}
--------

Catalytic receptors are cell‐surface proteins, usually dimeric in nature, which encompass ligand binding and functional domains in one polypeptide chain. The ligand binding domain is placed on the extracellular surface of the plasma membrane and separated from the functional domain by a single transmembrane‐spanning domain of 20‐25 hydrophobic amino acids. The functional domain on the intracellular face of the plasma membrane has catalytic activity, or interacts with particular enzymes, giving the superfamily of receptors its name. Endogenous agonists of the catalytic receptor superfamily are peptides or proteins, the binding of which may induce dimerization of the receptor, which is the functional version of the receptor.

Amongst the catalytic receptors, particular subfamilies may be readily identified dependent on the function of the enzymatic portion of the receptor. The smallest group is the particulate guanylyl cyclases of the natriuretic peptide receptor family. The most widely recognized group is probably the receptor tyrosine kinase (RTK) family, epitomized by the neurotrophin receptor family, where a crucial initial step is the activation of a signalling cascade by autophosphorylation of the receptor on intracellular tyrosine residue(s) catalyzed by enzyme activity intrinsic to the receptor. A third group is the extrinsic protein tyrosine kinase receptors, where the catalytic activity resides in a separate protein from the binding site. Examples of this group include the GDNF and ErbB receptor families, where one, catalytically silent, member of the heterodimer is activated upon binding the ligand, causing the second member of the heterodimer, lacking ligand binding capacity, to initiate signaling through tyrosine phosphorylation. A fourth group, the receptor threonine/serine kinase (RTSK) family, exemplified by TGF‐β and BMP receptors, has intrinsic serine/threonine protein kinase activity in the heterodimeric functional unit. A fifth group is the receptor tyrosine phosphatases (RTP), which appear to lack cognate ligands, but may be triggered by events such as cell:cell contact and have identified roles in the skeletal, hematopoietic and immune systems.

A further group of catalytic receptors for the Guide is the integrins, which have roles in cell:cell communication, often associated with signaling in the blood.

1.1. Family structure {#bph14751-sec-004}
---------------------

[S248 Cytokine receptor family](#bph14751-sec-005){ref-type="sec"}

[S249 IL‐2 receptor family](#bph14751-sec-007){ref-type="sec"}

[S251 IL‐3 receptor family](#bph14751-sec-011){ref-type="sec"}

[S252 IL‐6 receptor family](#bph14751-sec-014){ref-type="sec"}

[S254 IL‐12 receptor family](#bph14751-sec-018){ref-type="sec"}

[S255 Prolactin receptor family](#bph14751-sec-022){ref-type="sec"}

[S256 Interferon receptor family](#bph14751-sec-025){ref-type="sec"}

[S257 IL‐10 receptor family](#bph14751-sec-029){ref-type="sec"}

[S258 Immunoglobulin‐like family of IL‐1 receptors](#bph14751-sec-033){ref-type="sec"}

[S259 IL‐17 receptor family](#bph14751-sec-037){ref-type="sec"}

[S259 GDNF receptor family](#bph14751-sec-041){ref-type="sec"}

[S260 Integrins](#bph14751-sec-045){ref-type="sec"}

[S264 Pattern recognition receptors](#bph14751-sec-049){ref-type="sec"}

[S264 Toll‐like receptor family](#bph14751-sec-051){ref-type="sec"}

[S266 NOD‐like receptor family](#bph14751-sec-054){ref-type="sec"}

[S268 RIG‐I‐like receptor family](#bph14751-sec-058){ref-type="sec"}

[S269 Receptor guanylyl cyclase (RGC) family](#bph14751-sec-062){ref-type="sec"}

[S269 Transmembrane guanylyl cyclases](#bph14751-sec-064){ref-type="sec"}

[S270 Nitric oxide (NO)‐sensitive (soluble) guanylyl cyclase](#bph14751-sec-067){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=699>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=686>

[S271 Receptor tyrosine kinases (RTKs)](#bph14751-sec-071){ref-type="sec"}

[S272 Type I RTKs: ErbB (epidermal growth factor) receptor family](#bph14751-sec-073){ref-type="sec"}

[S273 Type II RTKs: Insulin receptor family](#bph14751-sec-077){ref-type="sec"}

[S274 Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family](#bph14751-sec-080){ref-type="sec"}

[S275 Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family](#bph14751-sec-083){ref-type="sec"}

[S275 Type V RTKs: FGF (fibroblast growth factor) receptor family](#bph14751-sec-086){ref-type="sec"}

[S276 Type VI RTKs: PTK7/CCK4](#bph14751-sec-089){ref-type="sec"}

[S277 Type VII RTKs: Neurotrophin receptor/ Trk family](#bph14751-sec-092){ref-type="sec"}

[S278 Type VIII RTKs: ROR family](#bph14751-sec-095){ref-type="sec"}

[S278 Type IX RTKs: MuSK](#bph14751-sec-097){ref-type="sec"}

[S279 Type X RTKs: HGF (hepatocyte growth factor) receptor family](#bph14751-sec-100){ref-type="sec"}

[S279 Type XI RTKs: TAM (TYRO3‐, AXL‐ and MER‐TK) receptor family](#bph14751-sec-103){ref-type="sec"}

[S280 Type XII RTKs: TIE family of angiopoietin receptors](#bph14751-sec-106){ref-type="sec"}

[S280 Type XIII RTKs: Ephrin receptor family](#bph14751-sec-108){ref-type="sec"}

[S281 Type XIV RTKs: RET](#bph14751-sec-110){ref-type="sec"}

[S282 Type XV RTKs: RYK](#bph14751-sec-113){ref-type="sec"}

[S282 Type XVI RTKs: DDR (collagen receptor) family](#bph14751-sec-116){ref-type="sec"}

[S283 Type XVII RTKs: ROS receptors](#bph14751-sec-119){ref-type="sec"}

[S283 Type XVIII RTKs: LMR family](#bph14751-sec-121){ref-type="sec"}

[S284 Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family](#bph14751-sec-124){ref-type="sec"}

[S284 Type XX RTKs: STYK1](#bph14751-sec-126){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=687>

[S286 Receptor serine/threonine kinase (RSTK) family](#bph14751-sec-130){ref-type="sec"}

[S286 Type I receptor serine/threonine kinases](#bph14751-sec-132){ref-type="sec"}

[S287 Type II receptor serine/threonine kinases](#bph14751-sec-135){ref-type="sec"}

[S287 Type III receptor serine/threonine kinases](#bph14751-sec-137){ref-type="sec"}

[S287 RSTK functional heteromers](#bph14751-sec-138){ref-type="sec"}

[S289 Receptor tyrosine phosphatase (RTP) family](#bph14751-sec-143){ref-type="sec"}

[S291 Tumour necrosis factor (TNF) receptor family](#bph14751-sec-146){ref-type="sec"}

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=301> {#bph14751-sec-005}
===========================================================================

1. Overview {#bph14751-sec-006}
-----------

Cytokines are not a clearly defined group of agents, other than having an impact on immune signalling pathways, although many cytokines have effects on other systems, such as in development. A feature of some cytokines, which allows them to be distinguished from hormones, is that they may be produced by "non‐secretory" cells, for example, endothelial cells. Within the cytokine receptor family, some subfamilies may be identified, which are described elsewhere in the Guide to PHARMACOLOGY, receptors for the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=334>, the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=303> family and the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=14>. Within this group of records are described Type I cytokine receptors, typified by interleukin receptors, and Type II cytokine receptors, exemplified by interferon receptors. These receptors possess a conserved extracellular region, known as the cytokine receptor homology domain (CHD), along with a range of other structural modules, including extracellular immunoglobulin (Ig)‐like and fibronectin type III (FBNIII)‐like domains, a transmembrane domain, and intracellular homology domains. An unusual feature of this group of agents is the existence of soluble and decoy receptors. These bind cytokines without allowing signalling to occur. A further attribute is the production of endogenous antagonist molecules, which bind to the receptors selectively and prevent signalling. A commonality of these families of receptors is the ligand‐induced homo‐ or hetero‐oligomerisation, which results in the recruitment of intracellular protein partners to evoke cellular responses, particularly in inflammatory or haematopoietic signalling. Although not an exclusive signalling pathway, a common feature of the majority of cytokine receptors is activation of the JAK/STAT pathway. This cascade is based around the protein tyrosine kinase activity of the Janus kinases (JAK), which phosphorylate the receptor and thereby facilitate the recruitment of signal transducers and activators of transcription (STATs). The activated homo‐ or heterodimeric STATs function principally as transcription factors in the nucleus. **Type I cytokine receptors** are characterized by two pairs of conserved cysteines linked via disulfide bonds and a C‐terminal WSXWS motif within their CHD. Type I receptors are commonly classified into five groups, based on sequence and structual homology of the receptor and its cytokine ligand, which is potentially more reflective of evolutionary relationships than an earlier scheme based on the use of common signal transducing chains within a receptor complex.

**Type II cytokine receptors** also have two pairs of conserved cysteines but with a different arrangement to Type I and also lack the WSXWS motif.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=305> {#bph14751-sec-007}
===========================================================================

1. Overview {#bph14751-sec-008}
-----------

The IL‐2 receptor family consists of one or more ligand‐selective subunits, and a common γ chain (γc): *IL2RG*, <http://www.uniprot.org/uniprot/P31785>), though IL‐4 and IL‐7 receptors can form complexes with other receptor chains. Receptors of this family associate with Jak1 and Jak3, primarily activating Stat5, although certain family members can also activate Stat1, Stat3, or Stat6. Ro264550 has been described as a selective IL‐2 receptor antagonist, which binds to IL‐2 \[[211](#bph14751-bib-0211){ref-type="ref"}\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2297><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2298><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2299><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2300><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2301>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1695> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1696> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2303> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1697> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2303> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1697> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1700> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1698> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2303> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1699> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2303> (Other subunit)Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4985> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6001](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6001), <http://www.uniprot.org/uniprot/P60568>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4996> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6014](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6014), <http://www.uniprot.org/uniprot/P05112>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4980> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5973](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5973), <http://www.uniprot.org/uniprot/P35225>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4996> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6014](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6014), <http://www.uniprot.org/uniprot/P05112>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4999> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6023](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6023), <http://www.uniprot.org/uniprot/P13232>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5000> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6029](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6029), <http://www.uniprot.org/uniprot/P15248>)Endogenous antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5878> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6000](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6000), <http://www.uniprot.org/uniprot/P18510>)--------Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4861> \[<http://www.ncbi.nlm.nih.gov/pubmed/8940020?dopt=AbstractPlus>\]--------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1701><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2302><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2304><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2305>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5975](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5975), <http://www.uniprot.org/uniprot/Q14627>------Subunits--<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1696> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1702> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2303> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1703> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2303> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1698> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1704> (Other subunit)Endogenous agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4981> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5977](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5977), <http://www.uniprot.org/uniprot/P40933>) \[<http://www.ncbi.nlm.nih.gov/pubmed/19710453?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4987> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6005](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6005), <http://www.uniprot.org/uniprot/Q9HBE4>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5083> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30743](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30743), <http://www.uniprot.org/uniprot/Q969D9>)CommentsDecoy receptor that binds <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4980> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5973](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5973), <http://www.uniprot.org/uniprot/P35225>) as a monomer.------

2. Subunits {#bph14751-sec-009}
-----------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1695><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1696><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2303><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1697><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1698>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6008](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6008), <http://www.uniprot.org/uniprot/P01589>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6009](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6009), <http://www.uniprot.org/uniprot/P14784>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6010](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6010), <http://www.uniprot.org/uniprot/P31785>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6015](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6015), <http://www.uniprot.org/uniprot/P24394>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6024](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6024), <http://www.uniprot.org/uniprot/P16871>Antibodies<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6880> (Binding) (p*K* ~d~ *\>* 8) \[[182](#bph14751-bib-0182){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6879> (Binding)----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7574> (Binding) (pIC~50~ 11.1) \[[146](#bph14751-bib-0146){ref-type="ref"}\]--

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1699><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1700><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1702><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1703><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1704>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6030](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6030), <http://www.uniprot.org/uniprot/Q01113>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5974](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5974), <http://www.uniprot.org/uniprot/P78552>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5978](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5978), <http://www.uniprot.org/uniprot/Q13261>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6006](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6006), <http://www.uniprot.org/uniprot/Q9HBE5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14281](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14281), <http://www.uniprot.org/uniprot/Q9HC73>

3. Further reading on IL‐2 receptor family {#bph14751-sec-010}
------------------------------------------

Leonard WJ *et al*. (2019) The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications *Immunity* **50**: 832‐850

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=306> {#bph14751-sec-011}
===========================================================================

1. Overview {#bph14751-sec-012}
-----------

The IL‐3 receptor family signal through a receptor complex comprising of a ligand‐specific α subunit and a common β chain (*CSF2RB*, <http://www.uniprot.org/uniprot/P32927>), which is associated with Jak2 and signals primarily through Stat5.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2307><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2308><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2309>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1705> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2306> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1706> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2306> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2306> (Other subunit)Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4994> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6011](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6011), <http://www.uniprot.org/uniprot/P08700>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4997> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6016](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6016), <http://www.uniprot.org/uniprot/P05113>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4934> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2438](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2438), <http://www.uniprot.org/uniprot/P09919>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4942> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2434](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2434), <http://www.uniprot.org/uniprot/P04141>)Selective antagonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5090> \[<http://www.ncbi.nlm.nih.gov/pubmed/12469943?dopt=AbstractPlus>\]--

2. Subunits {#bph14751-sec-013}
-----------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1705><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1706><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2306>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6012](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6012), <http://www.uniprot.org/uniprot/P26951>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6017](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6017), <http://www.uniprot.org/uniprot/Q01344>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2435](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2435), <http://www.uniprot.org/uniprot/P15509>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2436](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2436), <http://www.uniprot.org/uniprot/P32927>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4994> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6011](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6011), <http://www.uniprot.org/uniprot/P08700>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4997> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6016](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6016), <http://www.uniprot.org/uniprot/P05113>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4942> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2434](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2434), <http://www.uniprot.org/uniprot/P04141>)--Antibodies--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7674> (Binding) (p*K* ~d~ 8.7) \[[115](#bph14751-bib-0115){ref-type="ref"}\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7785> (Binding) (pIC50 9.9) \[[33](#bph14751-bib-0033){ref-type="ref"}\]--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=307> {#bph14751-sec-014}
===========================================================================

Overview {#bph14751-sec-015}
--------

The IL‐6 receptor family signal through a ternary receptor complex consisting of the cognate receptor and either the IL‐6 signal transducer gp130 (*IL6ST*, <http://www.uniprot.org/uniprot/P40189>) or the oncostatin M‐specific receptor, β subunit (*OSMR*, <http://www.uniprot.org/uniprot/Q99650>), which then activates the JAK/STAT, Ras/Raf/MAPK and PI 3‐kinase/PKB signalling modules. Unusually amongst the cytokine receptors, the CNTF receptor is a glycerophosphatidylinositol‐linked protein.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2310><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2311><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2316><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2312><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2313><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2314><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2315>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1708> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2317> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1709> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2317> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2318> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2317> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1710> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1714> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1711> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1713> (Other subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2317><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1713> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2317> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1714> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2317> (Other subunit)Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4998> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6018](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6018), <http://www.uniprot.org/uniprot/P05231>) (Murine NIH/3T3 fibroblasts with human IL6R exhibited a single class of binding sites for 125I‐labeled recombinant human interleukin‐6 (125I‐rhIL‐6) (Kd = 440 pM, 20,000 receptors per cell).) \[<http://www.ncbi.nlm.nih.gov/pubmed/1995637?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4976> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5966](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5966), <http://www.uniprot.org/uniprot/P20809>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6151> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3129](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3129) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19157](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19157), <http://www.uniprot.org/uniprot/Q14213> <http://www.uniprot.org/uniprot/Q14213>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4995> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19372](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19372), <http://www.uniprot.org/uniprot/Q6EBC2>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6150> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17412](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17412) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2364](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2364), <http://www.uniprot.org/uniprot/O75462> <http://www.uniprot.org/uniprot/Q9UBD9>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4897> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2169](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2169), <http://www.uniprot.org/uniprot/P26441>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5016> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6596](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6596), <http://www.uniprot.org/uniprot/P15018>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4906> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2499](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2499), <http://www.uniprot.org/uniprot/Q16619>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5035> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8506](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8506), <http://www.uniprot.org/uniprot/P13725>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5035>([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8506](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8506), <http://www.uniprot.org/uniprot/P13725>)Agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6971> \[<http://www.ncbi.nlm.nih.gov/pubmed/11033834?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18020592?dopt=AbstractPlus>\]----------Antibodies<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8363> (Binding) (p*K* ~d~ 12.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/25994180?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9093> (Binding) (p*K* ~d~ 8.9) \[[97](#bph14751-bib-0097){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881> (Binding) (p*K* ~d~ 8.6)------------

Subunits {#bph14751-sec-016}
--------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1708><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2317>Systematic nomenclatureinterleukin 6 receptorinterleukin 6 signal transducerCommon abbreviationIL6RIL6STHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6019](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6019), <http://www.uniprot.org/uniprot/P08887>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6021](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6021), <http://www.uniprot.org/uniprot/P40189>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4998> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6018](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6018), <http://www.uniprot.org/uniprot/P05231>) (IL6R) expressed stably in murine NIH/3T3 fibroblasts.exhibited a single class of binding sites for 125I‐labeled recombinant human interleukin‐6 (125I‐rhIL‐6) (Kd = 440 pM, 20,000 receptors per cell).) \[<http://www.ncbi.nlm.nih.gov/pubmed/1995637?dopt=AbstractPlus>\]--Antibodies<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999> (Binding) (p*K* ~d~ 10.6--11.1) \[[205](#bph14751-bib-0205){ref-type="ref"}\]--

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1709><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2318><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1710><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1711><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1713><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1714>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5967](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5967), <http://www.uniprot.org/uniprot/Q14626>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17290](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17290), <http://www.uniprot.org/uniprot/Q6UWB1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18969](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18969), <http://www.uniprot.org/uniprot/Q8NI17>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2170](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2170), <http://www.uniprot.org/uniprot/P26992>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6554](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6554), <http://www.uniprot.org/uniprot/P48357>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6597](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6597), <http://www.uniprot.org/uniprot/P42702>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8507](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8507), <http://www.uniprot.org/uniprot/Q99650>Endogenous agonists--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5015> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6553](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6553), <http://www.uniprot.org/uniprot/P41159>) \[<http://www.ncbi.nlm.nih.gov/pubmed/24743494?dopt=AbstractPlus>\] -- Mouse----

Further reading on IL‐6 receptor family {#bph14751-sec-017}
---------------------------------------

Ho LJ *et al*. (2015) Biological effects of interleukin‐6: Clinical applications in autoimmune diseases and cancers. *Biochem. Pharmacol*. **97**: 16‐26 <https://www.ncbi.nlm.nih.gov/pubmed/26080005?dopt=AbstractPlus>

Kang S *et al*. (2019) Targeting Interleukin‐6 Signaling in Clinic *Immunity* **50**: 1007‐1023

Murakami M *et al*. (2019) Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines *Immunity* **50**: 812‐831

Rothaug M *et al*. (2016) The role of interleukin‐6 signaling in nervous tissue. *Biochim. Biophys. Acta* **1863**: 1218‐27 <https://www.ncbi.nlm.nih.gov/pubmed/27016501?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=308> {#bph14751-sec-018}
===========================================================================

Overview {#bph14751-sec-019}
--------

IL‐12 receptors are a subfamily of the IL‐6 receptor family. IL12RB1 is shared between receptors for IL‐12 and IL‐23; the functional agonist at IL‐12 receptors is a heterodimer of IL‐12A/IL‐12B, while that for IL‐23 receptors is a heterodimer of IL‐12B/IL‐23A.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2292><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2293>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1715> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1716> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1717> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1715> (Ligand‐binding subunit)Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4977> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5969](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5969) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5970](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5970), <http://www.uniprot.org/uniprot/P29459> <http://www.uniprot.org/uniprot/P29460>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4978> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5970](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5970) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15488](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15488), <http://www.uniprot.org/uniprot/P29460>)

Subunits {#bph14751-sec-020}
--------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1715><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1716><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1717>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5971](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5971), <http://www.uniprot.org/uniprot/P42701>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5972](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5972), <http://www.uniprot.org/uniprot/Q99665>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19100](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19100), <http://www.uniprot.org/uniprot/Q5VWK5>

Further reading on IL‐12 receptor family {#bph14751-sec-021}
----------------------------------------

Wojno EDT *et al*. (2019) The Immunobiology of the Interleukin‐12 Family: Room for Discovery *Immunity* **50**: 851‐870

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=309> {#bph14751-sec-022}
===========================================================================

Overview {#bph14751-sec-023}
--------

Prolactin family receptors form homodimers in the presence of their respective ligands, associate exclusively with Jak2 and signal via Stat5.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1720><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1721><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3416](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3416), <http://www.uniprot.org/uniprot/P19235>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2439](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2439), <http://www.uniprot.org/uniprot/Q99062>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4263](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4263), <http://www.uniprot.org/uniprot/P10912>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9446](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9446), <http://www.uniprot.org/uniprot/P16471>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7217](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7217), <http://www.uniprot.org/uniprot/P40238>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4921> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3415](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3415), <http://www.uniprot.org/uniprot/P01588>) \[<http://www.ncbi.nlm.nih.gov/pubmed/16982323?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4934> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2438](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2438), <http://www.uniprot.org/uniprot/P09919>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4943> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4261](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4261), <http://www.uniprot.org/uniprot/P01241>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4944> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4262](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4262), <http://www.uniprot.org/uniprot/P01242>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5049> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9445](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9445), <http://www.uniprot.org/uniprot/P01236>) \[<http://www.ncbi.nlm.nih.gov/pubmed/4362846?dopt=AbstractPlus>\] -- Mouse, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4893> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2440](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2440) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2441](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2441), <http://www.uniprot.org/uniprot/P01243>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4894> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2442](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2442), <http://www.uniprot.org/uniprot/Q14406>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5063> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11795](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11795), <http://www.uniprot.org/uniprot/P40225>)Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7447> \[<http://www.ncbi.nlm.nih.gov/pubmed/16982323?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6969>----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6974>Selective agonists--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6961> \[<http://www.ncbi.nlm.nih.gov/pubmed/18783949?dopt=AbstractPlus>\]Antagonists----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7485> \[<http://www.ncbi.nlm.nih.gov/pubmed/10770982?dopt=AbstractPlus>\]----

Further reading on Prolactin receptor family {#bph14751-sec-024}
--------------------------------------------

Cabrera‐Reyes EA *et al*. (2017) Prolactin function and putative expression in the brain. *Endocrine* **57**: 199‐213 <https://www.ncbi.nlm.nih.gov/pubmed/28634745?dopt=AbstractPlus>

Goffin V. (2017) Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge. *Pharmacol. Ther*. **179**: 111‐126 <https://www.ncbi.nlm.nih.gov/pubmed/28549597?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=310> {#bph14751-sec-025}
===========================================================================

Overview {#bph14751-sec-026}
--------

The interferon receptor family includes receptors for type I (α, β κ and ω) and type II (γ) interferons. There are at least 13 different genes encoding IFN‐α subunits in a cluster on human chromosome 9p22: α1 (*IFNA1*, <http://www.uniprot.org/uniprot/P01562>), α2 (*IFNA2*, <http://www.uniprot.org/uniprot/P01563>), α4 (*IFNA4*, <http://www.uniprot.org/uniprot/P05014>), α5 (*IFNA5*, <http://www.uniprot.org/uniprot/P01569>), α6 (*IFNA6*, <http://www.uniprot.org/uniprot/P05013>), α7 (*IFNA7*, <http://www.uniprot.org/uniprot/P01567>), α8 (*IFNA8*, <http://www.uniprot.org/uniprot/P32881>), α10 (*IFNA10*, <http://www.uniprot.org/uniprot/P01566>), α13 (*IFNA13*, <http://www.uniprot.org/uniprot/P01562>), α14 (*IFNA14*, <http://www.uniprot.org/uniprot/P01570>), α16 (*IFNA16*, <http://www.uniprot.org/uniprot/P05015>), α17 (*IFNA17*, <http://www.uniprot.org/uniprot/P01571>) and α21 (*IFNA21*, <http://www.uniprot.org/uniprot/P01568>).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1898><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1899>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1723> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1724> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1725> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1726> (Other subunit)Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4955> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5417](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5417) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5419](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5419), <http://www.uniprot.org/uniprot/P01562>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4956> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5418](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5418), <http://www.uniprot.org/uniprot/P01566>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4957> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5420](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5420), <http://www.uniprot.org/uniprot/P01570>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4958> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5421](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5421), <http://www.uniprot.org/uniprot/P05015>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4959> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5422](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5422), <http://www.uniprot.org/uniprot/P01571>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4960> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5423](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5423), <http://www.uniprot.org/uniprot/P01563>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4961> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5424](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5424), <http://www.uniprot.org/uniprot/P01568>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4962> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5425](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5425), <http://www.uniprot.org/uniprot/P05014>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4963> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5426](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5426), <http://www.uniprot.org/uniprot/P01569>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4964> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5427](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5427), <http://www.uniprot.org/uniprot/P05013>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4965> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5428](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5428), <http://www.uniprot.org/uniprot/P01567>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4966> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5429](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5429), <http://www.uniprot.org/uniprot/P32881>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4967> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5434](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5434), <http://www.uniprot.org/uniprot/P01574>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4969> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21714](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21714), <http://www.uniprot.org/uniprot/Q9P0W0>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4970> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5448](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5448), <http://www.uniprot.org/uniprot/P05000>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4968> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5438](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5438), <http://www.uniprot.org/uniprot/P01579>)Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7462> \[<http://www.ncbi.nlm.nih.gov/pubmed/10607680?dopt=AbstractPlus>\]--

Subunits {#bph14751-sec-027}
--------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1723><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1724><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1725><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1726>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5432](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5432), <http://www.uniprot.org/uniprot/P17181>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5433](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5433), <http://www.uniprot.org/uniprot/P48551>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5439](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5439), <http://www.uniprot.org/uniprot/P15260>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5440](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5440), <http://www.uniprot.org/uniprot/P38484>Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4967> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5434](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5434), <http://www.uniprot.org/uniprot/P01574>) \[<http://www.ncbi.nlm.nih.gov/pubmed/29311663?dopt=AbstractPlus>\]------Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7462> \[<http://www.ncbi.nlm.nih.gov/pubmed/10607680?dopt=AbstractPlus>\]------Antibodies<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8258> (Binding) (p*K* ~d~ \>10) \[[26](#bph14751-bib-0026){ref-type="ref"}\]------

Further reading on Interferon receptor family {#bph14751-sec-028}
---------------------------------------------

Kotenko SV *et al*. (2017) Contribution of type III interferons to antiviral immunity: location, location, location. *J. Biol. Chem*. **292**: 7295‐7303 <https://www.ncbi.nlm.nih.gov/pubmed/28289095?dopt=AbstractPlus>

Lazear HM *et al*. (2019) Shared and Distinct Functions of Type I and Type III Interferons *Immunity* **50**: 907‐923

Ng CT *et al*. (2016) Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes. *Cell* **164**: 349‐52 <https://www.ncbi.nlm.nih.gov/pubmed/26824652?dopt=AbstractPlus>

Schreiber G. (2017) The molecular basis for differential type I interferon signaling. *J. Biol. Chem*. **292**: 7285‐7294 <https://www.ncbi.nlm.nih.gov/pubmed/28289098?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=311> {#bph14751-sec-029}
===========================================================================

Overview {#bph14751-sec-030}
--------

The IL‐10 family of receptors are heterodimeric combinations of family members: IL10RA/IL10RB responds to IL‐10; IL20RA/IL20RB responds to IL‐19, IL‐20 and IL‐24; IL22RA1/IL20RB responds to IL‐20 and IL‐24; IL22RA1/IL10RB responds to IL‐22; IFNLR1(previouly known as IL28RA)/IL10RB responds to IFN‐λ1, ‐λ2 and ‐λ3 (previouly known as IL‐29, IL‐28A and IL‐28B respectively).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1900><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1901><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1902><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1903><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1732><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1904>HGNC, UniProt--------[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14901](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14901), <http://www.uniprot.org/uniprot/Q969J5>--Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1727> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1728> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1729> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1730> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1731> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1730> (Ligand‐binding subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1731> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1728> (Ligand‐binding subunit)--<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1733> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1728> (Other subunit)Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4975> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5962](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5962), <http://www.uniprot.org/uniprot/P22301>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4984> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5990](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5990), <http://www.uniprot.org/uniprot/Q9UHD0>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4986> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6002](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6002), <http://www.uniprot.org/uniprot/Q9NYY1>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4990> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11346](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11346), <http://www.uniprot.org/uniprot/Q13007>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4986> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6002](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6002), <http://www.uniprot.org/uniprot/Q9NYY1>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4990> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11346](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11346), <http://www.uniprot.org/uniprot/Q13007>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4988> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14900](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14900), <http://www.uniprot.org/uniprot/Q9GZX6>)--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4993> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18363](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18363), <http://www.uniprot.org/uniprot/Q8IU54>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4991> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18364](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18364), <http://www.uniprot.org/uniprot/Q8IZJ0>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4992> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18365](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18365), <http://www.uniprot.org/uniprot/Q8IZI9>)Comments--------Soluble decoy receptor that binds <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4988> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14900](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14900), <http://www.uniprot.org/uniprot/Q9GZX6>) as a monomer.--

Subunits {#bph14751-sec-031}
--------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1727><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1728><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1729><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1730><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1731><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1733>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5964](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5964), <http://www.uniprot.org/uniprot/Q13651>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5965](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5965), <http://www.uniprot.org/uniprot/Q08334>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6003](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6003), <http://www.uniprot.org/uniprot/Q9UHF4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6004](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6004), <http://www.uniprot.org/uniprot/Q6UXL0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13700](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13700), <http://www.uniprot.org/uniprot/Q8N6P7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18584](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18584), <http://www.uniprot.org/uniprot/Q8IU57>

Further reading on IL‐10 receptor family {#bph14751-sec-032}
----------------------------------------

Felix J *et al*. (2017) Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures. *Nat. Rev. Immunol*. **17**: 112‐129 <https://www.ncbi.nlm.nih.gov/pubmed/28028310?dopt=AbstractPlus>

Ouyang W *et al*. (2019) IL‐10 Family Cytokines IL‐10 and IL‐22: from Basic Science to Clinical Translation *Immunity* **50**: 871‐891

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=312> {#bph14751-sec-033}
===========================================================================

Overview {#bph14751-sec-034}
--------

The immunoglobulin‐like family of IL‐1 receptors are heterodimeric receptors made up of a cognate receptor subunit and an IL‐1 receptor accessory protein, [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5995](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5995) (<http://www.uniprot.org/uniprot/Q9NPH3>, also known as C3orf13, IL‐1RAcP, IL1R3). They are characterised by extracellular immunoglobulin‐like domains and an intracellular Toll/Interleukin‐1R (TIR) domain.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1905><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1906><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1907><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2321><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1908>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1734> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1897> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1735> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1897> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1736> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1897> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2319> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1897> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1737> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2320> (Other subunit)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972> (p*K* ~d~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/1834644?dopt=AbstractPlus>\]--------Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4973> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5991](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5991), <http://www.uniprot.org/uniprot/P01583>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4974> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5992](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5992), <http://www.uniprot.org/uniprot/P01584>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5880> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16028](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16028), <http://www.uniprot.org/uniprot/O95760>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5881> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15562](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15562), <http://www.uniprot.org/uniprot/Q9UHA7>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5882> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15564](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15564), <http://www.uniprot.org/uniprot/Q9NZH7>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5883> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15741](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15741), <http://www.uniprot.org/uniprot/Q9NZH8>)--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4983> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5986](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5986), <http://www.uniprot.org/uniprot/Q14116>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6149> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15563](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15563), <http://www.uniprot.org/uniprot/Q9NZH6>)Endogenous antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5878> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6000](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6000), <http://www.uniprot.org/uniprot/P18510>)--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5879> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15561](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15561), <http://www.uniprot.org/uniprot/Q9UBH0>)----Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4861> \[<http://www.ncbi.nlm.nih.gov/pubmed/8940020?dopt=AbstractPlus>\]--------Comments----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5879> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15561](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15561), <http://www.uniprot.org/uniprot/Q9UBH0>) is a highly specific antagonist of the response to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5883> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15741](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15741), <http://www.uniprot.org/uniprot/Q9NZH8>).Decoy receptor that binds <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4973> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5991](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5991), <http://www.uniprot.org/uniprot/P01583>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4974> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5992](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5992), <http://www.uniprot.org/uniprot/P01584>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5878> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6000](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6000), <http://www.uniprot.org/uniprot/P18510>).--

Subunits {#bph14751-sec-035}
--------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1734><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2319><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1735><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1736><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1737>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5993](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5993), <http://www.uniprot.org/uniprot/P14778>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5994](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5994), <http://www.uniprot.org/uniprot/P27930>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5998](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5998), <http://www.uniprot.org/uniprot/Q01638>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5999](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5999), <http://www.uniprot.org/uniprot/Q9HB29>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5988](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5988), <http://www.uniprot.org/uniprot/Q13478>

Further reading on Immunoglobulin‐like family of IL‐1 receptors {#bph14751-sec-036}
---------------------------------------------------------------

Afonina IS *et al*. (2015) Proteolytic Processing of Interleukin‐1 Family Cytokines: Variations on a Common Theme. *Immunity* **42**: 991‐1004 <https://www.ncbi.nlm.nih.gov/pubmed/26084020?dopt=AbstractPlus>

Mantovani A *et al*. (2019) Interleukin‐1 and Related Cytokines in the Regulation of Inflammation and *Immunity Immunity* **50**: 778‐795

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=313> {#bph14751-sec-037}
===========================================================================

Overview {#bph14751-sec-038}
--------

The IL17 cytokine family consists of six ligands (IL‐17A‐F), which signal through five receptors (IL‐17RA‐E).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2294><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2295><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2296>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1738> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1740> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1739> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1738> (Other subunit)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1742> (Ligand‐binding subunit), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1738> (Other subunit)Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4982> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5981](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5981), <http://www.uniprot.org/uniprot/Q16552>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5874> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5981](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5981) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16404](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16404), <http://www.uniprot.org/uniprot/Q16552> <http://www.uniprot.org/uniprot/Q96PD4>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5873> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16404](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16404), <http://www.uniprot.org/uniprot/Q96PD4>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5877> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5982](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5982), <http://www.uniprot.org/uniprot/Q9UHF5>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5876> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13765](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13765), <http://www.uniprot.org/uniprot/Q9H293>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5875> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5983](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5983), <http://www.uniprot.org/uniprot/Q9P0M4>)

Subunits {#bph14751-sec-039}
--------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1738><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1739><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1740><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1741><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1742>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5985](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5985), <http://www.uniprot.org/uniprot/Q96F46>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18015](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18015), <http://www.uniprot.org/uniprot/Q9NRM6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18358](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18358), <http://www.uniprot.org/uniprot/Q8NAC3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17616](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17616), <http://www.uniprot.org/uniprot/Q8NFM7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18439](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18439), <http://www.uniprot.org/uniprot/Q8NFR9>Antibodies<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7540> (Binding) (p*K* ~d~ 9.2) \[213\]--------Comments------The endogenous agonist for this receptor is unknown.--

Further reading on IL‐17 receptor family {#bph14751-sec-040}
----------------------------------------

Beringer A *et al*. (2016) IL‐17 in Chronic Inflammation: From Discovery to Targeting. *Trends Mol Med* **22**: 230‐241 <https://www.ncbi.nlm.nih.gov/pubmed/26837266?dopt=AbstractPlus>

Lubberts E. (2015) The IL‐23‐IL‐17 axis in inflammatory arthritis. *Nat Rev Rheumatol* **11**: 415‐29 <https://www.ncbi.nlm.nih.gov/pubmed/25907700?dopt=AbstractPlus>

McGeachy MJ *et al*. (2019) The IL‐17 Family of Cytokines in Health and Disease *Immunity* **50**: 892‐906

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=314> {#bph14751-sec-041}
===========================================================================

Overview {#bph14751-sec-042}
--------

GDNF family receptors (provisional nomenclature) are extrinsic tyrosine kinase receptors. Ligand binding to the extracellular domain of the glycosylphosphatidylinositol‐linked cell‐surface receptors (tabulated below) activates a transmembrane tyrosine kinase enzyme, [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9967](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9967) (see <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304>). The endogenous ligands are typically dimeric, linked through disulphide bridges: glial cell‐derived neurotrophic factor <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4940> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4232](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4232), <http://www.uniprot.org/uniprot/P39905>) (211 aa); <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5032> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8007](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8007), <http://www.uniprot.org/uniprot/Q99748>) (197 aa); <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4871> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:727](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:727), <http://www.uniprot.org/uniprot/Q5T4W7>) (237 aa) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5045> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9579](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9579), <http://www.uniprot.org/uniprot/O60542>) (PSPN, 156 aa).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1743><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1744><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1745><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1746>Common abbreviationGFRα1GFRα2GFRα3GFRα4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4243](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4243), <http://www.uniprot.org/uniprot/P56159>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4244](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4244), <http://www.uniprot.org/uniprot/O00451>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4245](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4245), <http://www.uniprot.org/uniprot/O60609>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13821](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13821), <http://www.uniprot.org/uniprot/Q9GZZ7>Potency order<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4940> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4232](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4232), <http://www.uniprot.org/uniprot/P39905>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5032> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8007](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8007), <http://www.uniprot.org/uniprot/Q99748>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4871> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:727](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:727), <http://www.uniprot.org/uniprot/Q5T4W7>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5032> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8007](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8007), <http://www.uniprot.org/uniprot/Q99748>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4940> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4232](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4232), <http://www.uniprot.org/uniprot/P39905>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4871> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:727](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:727), <http://www.uniprot.org/uniprot/Q5T4W7>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5045> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9579](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9579), <http://www.uniprot.org/uniprot/O60542>)Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4851> (p*K* ~d~ 10.2--11.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9192898?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8657309?dopt=AbstractPlus>\]------

Comments {#bph14751-sec-043}
--------

Inhibitors of other receptor tyrosine kinases, such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5056>, which inhibits VEGF receptor function, may also inhibit Ret function \[<http://www.ncbi.nlm.nih.gov/pubmed/17032739?dopt=AbstractPlus>\]. Mutations of RET and GDNF genes may be involved in Hirschsprung&apos;s disease, which is characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction.

Further reading on GDNF receptor family {#bph14751-sec-044}
---------------------------------------

Allen SJ *et al*. (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration. *Pharmacol. Ther*. **138**: 155‐75 <https://www.ncbi.nlm.nih.gov/pubmed/23348013?dopt=AbstractPlus>

Ibáñez CF *et al*. (2017) Biology of GDNF and its receptors ‐ Relevance for disorders of the central nervous system. *Neurobiol. Dis*. **97**: 80‐89 <https://www.ncbi.nlm.nih.gov/pubmed/26829643?dopt=AbstractPlus>

Merighi A. (2016) Targeting the glial‐derived neurotrophic factor and related molecules for controlling normal and pathologic pain. *Expert Opin. Ther. Targets* **20**: 193‐208 <https://www.ncbi.nlm.nih.gov/pubmed/26863504?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=760> {#bph14751-sec-045}
===========================================================================

Overview {#bph14751-sec-046}
--------

Integrins are unusual signalling proteins that function to signal both from the extracellular environment into the cell, but also from the cytoplasm to the external of the cell. The intracellular signalling cascades associated with integrin activation focus on protein kinase activities, such as focal adhesion kinase and Src. Based on this association between extracellular signals and intracellular protein kinase activity, we have chosen to include integrins in the 'Catalytic receptors' section of the database until more stringent criteria from NC‐IUPHAR allows precise definition of their classification.

Integrins are heterodimeric entities, composed of α and β subunits, each 1TM proteins, which bind components of the extracellular matrix or counter‐receptors expressed on other cells. One class of integrin contains an inserted domain (I) in its α subunit, and if present (in α1, α2, α10, α11, αD, αE, αL, αM and αX), this I domain contains the ligand binding site. All β subunits possess a similar I‐like domain, which has the capacity to bind ligand, often recognising the RGD motif. The presence of an a subunit I domain precludes ligand binding through the β subunit. Integrins provide a link between ligand and the actin cytoskeleton (through typically short intracellular domains). Integrins bind several divalent cations, including a Mg^2+^ ion in the I or I‐like domain that is essential for ligand binding. Other cation binding sites may regulate integrin activity or stabilise the 3D structure. Integrins regulate the activity of particular protein kinases, including focal adhesion kinase and integrin‐linked kinase. Cellular activation regulates integrin ligand affinity via inside‐out signalling and ligand binding to integrins can regulate cellular activity *via* outsidein signalling.

Several drugs that target integrins are in clinical use including: (1) <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6584> (αIIbβ3) for short term prevention of coronary thrombosis, (2) <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7437> (α4β7) to reduce gastrointestinal inflammation, and (3) <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6591> (α4β1) in some cases of severe multiple sclerosis.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2577><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2578><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2579><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2580>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2455>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2437><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2455>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2440><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2457>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2441><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2455>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2443>Ligandscollagen, laminincollagen, laminin, thrombospondin<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6749> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3661](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3661) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3662](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3662) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3694](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3694), <http://www.uniprot.org/uniprot/P02671> <http://www.uniprot.org/uniprot/P02675> <http://www.uniprot.org/uniprot/P02679>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6754> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3778](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3778), <http://www.uniprot.org/uniprot/P02751>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6755> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12726](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12726), <http://www.uniprot.org/uniprot/P04275>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6746> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12724](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12724), <http://www.uniprot.org/uniprot/P04004>), thrombospondin<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6754> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3778](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3778), <http://www.uniprot.org/uniprot/P02751>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6758> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12663](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12663), <http://www.uniprot.org/uniprot/P19320>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6753> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11255](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11255), <http://www.uniprot.org/uniprot/P10451>), thrombospondinInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6581> (pIC~50~ 9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/12727812?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6582> (pIC~50~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/19141632?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6586> (pIC~50~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/23644213?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6588> (p*K* ~i~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/7955174?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8485125?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6587> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/7966149?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6585> (pIC~50~ 6.2--6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/10999999?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6589> (pIC~50~ 8.3--9) \[<http://www.ncbi.nlm.nih.gov/pubmed/10072689?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6590>Antibodies----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6584> (Binding) \[[35](#bph14751-bib-0035){ref-type="ref"}\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6591> (Inhibition) \[<http://www.ncbi.nlm.nih.gov/pubmed/15293871?dopt=AbstractPlus>\]Comments------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6759> is used as a probe at this receptor.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2770><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2581><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2867><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2868>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2443>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2461><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2455>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2444><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2455>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2445><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2455>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2438>Ligands--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6754> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3778](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3778), <http://www.uniprot.org/uniprot/P02751>)laminincollagenAntibodies<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7437> (Antagonist) (pIC~50~ 8.3) \[[179](#bph14751-bib-0179){ref-type="ref"}\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10236> (Binding) (p*K* ~d~ 9.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17786386?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18042290?dopt=AbstractPlus>\]----

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2869><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2799><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2582><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2583>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2455>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2439><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2450>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2461><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2456>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2451><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2457>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2453>LigandscollagenE‐cadherin<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6757> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5344](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5344), <http://www.uniprot.org/uniprot/P05362>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6756> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5345](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5345), <http://www.uniprot.org/uniprot/P13598>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6746> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12724](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12724), <http://www.uniprot.org/uniprot/P04004>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6754> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3778](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3778), <http://www.uniprot.org/uniprot/P02751>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6749> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3661](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3661) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3662](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3662) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3694](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3694), <http://www.uniprot.org/uniprot/P02671> <http://www.uniprot.org/uniprot/P02675> <http://www.uniprot.org/uniprot/P02679>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6753> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11255](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11255), <http://www.uniprot.org/uniprot/P10451>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6755> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12726](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12726), <http://www.uniprot.org/uniprot/P04275>), thrombospondin, tenascinActivators------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9284> (p*K* ~d~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/20508901?dopt=AbstractPlus>\]Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6592> (pIC~50~ 7.4--7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/11052808?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6594> (pIC~50~ 11.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/15634795?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6595> (pIC~50~ 11.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/15634795?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6597> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/11855984?dopt=AbstractPlus>\]Antibodies------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6596> (Binding) (p*K* ~d~ 6.3) \[[237](#bph14751-bib-0237){ref-type="ref"}\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2437><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2440><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2441><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2442><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2443><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2444>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6134](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6134), <http://www.uniprot.org/uniprot/P56199>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6137](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6137), <http://www.uniprot.org/uniprot/P08514>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6138](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6138), <http://www.uniprot.org/uniprot/P17301>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6139](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6139), <http://www.uniprot.org/uniprot/P26006>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6140](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6140), <http://www.uniprot.org/uniprot/P13612>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6141](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6141), <http://www.uniprot.org/uniprot/P08648>Ligands------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8849> (Binding) (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19055415?dopt=AbstractPlus>\]----Antibodies--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6591> (Inhibition) \[<http://www.ncbi.nlm.nih.gov/pubmed/15293871?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10236> (Binding) (p*K* ~d~ 9.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17786386?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18042290?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2445><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2446><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2447><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2448><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2438><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2439><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2449>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6142](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6142), <http://www.uniprot.org/uniprot/P23229>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6143](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6143), <http://www.uniprot.org/uniprot/Q13683>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6144](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6144), <http://www.uniprot.org/uniprot/P53708>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6145](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6145), <http://www.uniprot.org/uniprot/Q13797>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6135](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6135), <http://www.uniprot.org/uniprot/O75578>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6136](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6136), <http://www.uniprot.org/uniprot/Q9UKX5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6146](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6146), <http://www.uniprot.org/uniprot/Q13349>

Nomenclature<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2450><https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2451><https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2452><https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2453><https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2454><https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2455>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6147](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6147), <http://www.uniprot.org/uniprot/P38570>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6148](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6148), <http://www.uniprot.org/uniprot/P20701>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6149](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6149), <http://www.uniprot.org/uniprot/P11215>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6150](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6150), <http://www.uniprot.org/uniprot/P06756>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6152](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6152), <http://www.uniprot.org/uniprot/P20702>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6153](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6153), <http://www.uniprot.org/uniprot/P05556>Antagonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7533> (Inhibition) \[[18](#bph14751-bib-0018){ref-type="ref"}, <http://www.ncbi.nlm.nih.gov/pubmed/24900456?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9689> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/14561098?dopt=AbstractPlus>\]----Antibodies--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6593> (Binding) (p*K* ~d~ 11.4) \[[100](#bph14751-bib-0100){ref-type="ref"}\]--------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2456><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2457><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2458><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2459><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2460><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2461><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2462>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6155](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6155), <http://www.uniprot.org/uniprot/P05107>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6156](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6156), <http://www.uniprot.org/uniprot/P05106>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6158](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6158), <http://www.uniprot.org/uniprot/P16144>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6160](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6160), <http://www.uniprot.org/uniprot/P18084>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6161](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6161), <http://www.uniprot.org/uniprot/P18564>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6162](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6162), <http://www.uniprot.org/uniprot/P26010>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6163](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6163), <http://www.uniprot.org/uniprot/P26012>

Comments: Integrin ligands {#bph14751-sec-047}
--------------------------

**Collagen** is the most abundant protein in metazoa, rich in glycine and proline residues, made up of cross‐linked triple helical structures, generated primarily by fibroblasts. Extensive post‐translational processing is conducted by prolyl and lysyl hydroxylases, as well as transglutaminases. Over 40 genes for collagen‐α subunits have been identified in the human genome. The collagen‐binding integrins α1β1, α2β1, α10β1 and α11β1 recognise a range of triple‐helical peptide motifs including GFOGER (O = hydroxyproline), a synthetic peptide derived from the primary sequence of collagen I (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4898> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2197>, <http://www.uniprot.org/uniprot/P02452>)) and collagen II (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4899> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2200>, <http://www.uniprot.org/uniprot/P02458>)).

**Laminin** is an extracellular glycoprotein composed of α, β and γ chains, for which five, four and three genes, respectively, are identified in the human genome. It binds to α1β1, α2β1, α3,β1, α7β1 and α6β4 integrins10.

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6749> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3661](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3661) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3662](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3662) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3694](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3694), <http://www.uniprot.org/uniprot/P02671> <http://www.uniprot.org/uniprot/P02675> <http://www.uniprot.org/uniprot/P02679>) is a glycosylated hexamer composed of two α ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3661](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3661), <http://www.uniprot.org/uniprot/P02671>), two β ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3662](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3662), <http://www.uniprot.org/uniprot/P02675>) and two γ ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3694](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3694), <http://www.uniprot.org/uniprot/P02679>,) subunits, linked by disulphide bridges. It is found in plasma and alpha granules of platelets. It forms cross‐links between activated platelets mediating aggregation by binding αIIbβ3; proteolysis by thrombin cleaves short peptides termed fibrinopeptides to generate fibrin, which polymerises as part of the blood coagulation cascade.

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6754> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3778](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3778), <http://www.uniprot.org/uniprot/P02751>) is a disulphide‐linked homodimer found as two major forms; a soluble dimeric form found in the plasma and a tissue version that is polymeric, which is secreted into the extracellular matrix by fibroblasts. Splice variation of the gene product ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3778](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3778), <http://www.uniprot.org/uniprot/P02751>) generates multiple isoforms.

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6746> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12724](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12724), <http://www.uniprot.org/uniprot/P04004>) is a serum glycoprotein and extracellular matrix protein which is found either as a monomer or, following proteolysis, a disulphide ‐linked dimer.

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6753> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11255](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11255), <http://www.uniprot.org/uniprot/P10451>) forms an integral part of the mineralized matrix in bone, where it undergoes extensive posttranslation processing, including proteolysis and phosphorylation.

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6755> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12726](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12726), <http://www.uniprot.org/uniprot/P04275>) is a glycoprotein synthesised in vascular endothelial cells as a disulphide‐linked homodimer, but multimerises further in plasma and is deposited on vessel wall collagen as a high molecular weight multimer. It is responsible for capturing platelets under arterial shear flow (*via* GPIb) and in thrombus propagation (via integrin αIIbβ3).
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Pattern Recognition Receptors (PRRs, \[<http://www.ncbi.nlm.nih.gov/pubmed/20303872?dopt=AbstractPlus>\]) (**nomenclature as agreed by [NC‐IUPHAR]{.ul} sub‐committee on Pattern Recognition Receptors**, \[<http://www.ncbi.nlm.nih.gov/pubmed/25829385?dopt=AbstractPlus>\]) participate in the innate immune response to microbial agents, the stimulation of which leads to activation of intracellular enzymes and regulation of gene transcription. PRRs express multiple leucine‐rich regions to bind a range of microbially‐derived ligands, termed PAMPs or pathogen‐associated molecular patterns or endogenous ligands, termed DAMPS or damage‐associated molecular patterns. These include peptides, carbohydrates, peptidoglycans, lipoproteins, lipopolysaccharides, and nucleic acids. PRRs include both cell‐surface and intracellular proteins. PRRs may be divided into signalling‐associated members, identified here, and endocytic members, the function of which appears to be to recognise particular microbial motifs for subsequent cell attachment, internalisation and destruction. Some are involved in inflammasome formation, and modulation of IL‐1β cleavage and secretion, and others in the initiation of the type I interferon response.

PRRs included in the Guide To PHARMACOLOGY are:

**Catalytic PRRs** (see links below this overview)

Toll‐like receptors (TLRs)

Nucleotide‐binding oligomerization domain, leucine‐rich repeat containing receptors (NLRs, also known as NOD (Nucleotide oligomerisation domain)‐like receptors)

RIG‐I‐like receptors (RLRs)

<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1620> and <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1621>

**Non‐catalytic PRRs**

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=942> (ALRs)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=945>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=929>

<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2843> (RAGE)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=316> {#bph14751-sec-051}
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Members of the toll‐like family of receptors (nomenclature recommended by the NC‐IUPHAR subcommittee on pattern recognition receptors, \[<http://www.ncbi.nlm.nih.gov/pubmed/25829385?dopt=AbstractPlus>\]) share significant homology with the interleukin‐1 receptor family and appear to require dimerization either as homo‐ or heterodimers for functional activity. Heterodimerization appears to influence the potency of ligand binding substantially (*e.g*. TLR1/2 and TLR2/6, \[<http://www.ncbi.nlm.nih.gov/pubmed/11431423?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12077222?dopt=AbstractPlus>\]). TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are cell‐surface proteins, while other members are associated with intracellular organelles, signalling through the MyD88‐dependent pathways (with the exception of TLR3). As well as responding to exogenous infectious agents, it has been suggested that selected members of the family may be activated by endogenous ligands, such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4953> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5261](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5261), <http://www.uniprot.org/uniprot/P10809>) \[<http://www.ncbi.nlm.nih.gov/pubmed/10623794?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1751><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1752><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1753><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1755>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11847](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11847), <http://www.uniprot.org/uniprot/Q15399>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11848](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11848), <http://www.uniprot.org/uniprot/O60603>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11849](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11849), <http://www.uniprot.org/uniprot/O15455>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11850](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11850), <http://www.uniprot.org/uniprot/O00206>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11851](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11851), <http://www.uniprot.org/uniprot/O60602>Agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8888> \[<http://www.ncbi.nlm.nih.gov/pubmed/23098072?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5044> \[<http://www.ncbi.nlm.nih.gov/pubmed/10364168?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10384090?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5047> \[<http://www.ncbi.nlm.nih.gov/pubmed/11607032?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5019> \[<http://www.ncbi.nlm.nih.gov/pubmed/9851930?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2770> \[<http://www.ncbi.nlm.nih.gov/pubmed/10644670?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4931> \[<http://www.ncbi.nlm.nih.gov/pubmed/11323673?dopt=AbstractPlus>\]Selective antagonists------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9036> \[<http://www.ncbi.nlm.nih.gov/pubmed/16373689?dopt=AbstractPlus>\]--CommentsFunctions as a heterodimer with TLR2 in detection of triacylated lipoproteins. Activated by the synthetic analogue <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8558>.Functions as a heterodimer with either TLR1 or TLR6 in the detection of triacylated and diacylated lipopeptides respectively. TLR1/2 and 2/6 heterodimers can be activated by the synthetic lipopeptides <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8558> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8560> respectively. There is some debate in the field as to whether or not peptidoglycan is a direct agonist of TLR2, or whether the early studies reporting this contained contaminating lipoproteins.Involved in endosomal detection of dsRNA; pro‐inflammatory.<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4919> (E5564) is a lipid A analogue, which has been described as a TLR4 antagonist \[<http://www.ncbi.nlm.nih.gov/pubmed/9820516?dopt=AbstractPlus>\]. TLR4 signals in conjunction with the co‐factor <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2890>.Involved in the detection of bacterial flagellin; pro‐inflammatory.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1756><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1757><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1758><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1760><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1761>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16711](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16711), <http://www.uniprot.org/uniprot/Q9Y2C9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15631](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15631), <http://www.uniprot.org/uniprot/Q9NYK1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15632](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15632), <http://www.uniprot.org/uniprot/Q9NR97>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15633](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15633), <http://www.uniprot.org/uniprot/Q9NR96>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15634](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15634), <http://www.uniprot.org/uniprot/Q9BXR5>--Agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5051> \[<http://www.ncbi.nlm.nih.gov/pubmed/11812998?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12032557?dopt=AbstractPlus>, 121\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5003> \[121\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5018> \[<http://www.ncbi.nlm.nih.gov/pubmed/14579267?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5051> \[<http://www.ncbi.nlm.nih.gov/pubmed/11812998?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12032557?dopt=AbstractPlus>, 121\]------Antagonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198> (pIC~50~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/24342772?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/24342772?dopt=AbstractPlus>\]----CommentsFunctions as a heterodimer with TLR2. Involved in the pro‐inflammatory response to diacylated bacterial lipopeptides.Activated by imidazoquinoline derivatives and RNA oligoribonucleotides. Involved in endosomal detection of ssRNA; pro‐inflammatory.Activated by imidazoquinoline derivatives and RNA oligoribonucleotides. Endosomal detection of ssRNA; pro‐inflammatory.Toll‐like receptor 9 interacts with unmethylated CpG dinucleotides from bacterial DNA \[<http://www.ncbi.nlm.nih.gov/pubmed/11130078?dopt=AbstractPlus>\]. Activated by CpG rich DNA sequences; pro‐inflammatory.TLR10 is the only pattern‐recognition receptor without known ligand specificity and biological function. Evidence suggests it plays a modulatory role with predominantly inhibitory (anti‐inflammatory) actions \[<http://www.ncbi.nlm.nih.gov/pubmed/25288745?dopt=AbstractPlus>\]. Murine TLR10 has a retroviral insertion that makes it non‐functional.Found in mouse

Further reading on Toll‐like receptor family {#bph14751-sec-053}
--------------------------------------------
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=317> {#bph14751-sec-054}
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The nucleotide‐binding oligomerization domain, leucine‐rich repeat (NLR) family of receptors (nomenclature recommended by the NC‐IUPHAR subcommittee on pattern recognition receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/25829385?dopt=AbstractPlus>\]) share a common domain organisation. This consists of an N‐terminal effector domain, a central nucleotidebinding and oligomerization domain (NOD; also referred to as a NACHT domain), and C‐terminal leucine‐rich repeats (LRR) which have regulatory and ligand recognition functions. The type of effector domain has resulted in the division of NLR family members into two major sub‐families, NLRC and NLRP, along with three smaller sub‐families NLRA, NLRB and NLRX \[<http://www.ncbi.nlm.nih.gov/pubmed/18341998?dopt=AbstractPlus>\]. NLRC members express an N‐terminal caspase recruitment domain (CARD) and NLRP members an N‐terminal Pyrin domain (PYD).

Upon activation the NLRC family members NOD1 (NLRC1) and NOD2 (NLRC2) recruit a serine/threonine kinase <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2190> (receptor interacting serine/threonine kinase 2, <http://www.uniprot.org/uniprot/O43353>, also known as CARD3, CARDIAK, RICK, RIP2) leading to signalling through NF*κ*B and MAP kinase. Activation of NLRC4 (previously known as IPAF) and members of the NLRP3 family, including NLRP1 and NLRP3, leads to formation of a large multiprotein complex known as the inflammasome. In addition to NLR proteins other key members of the inflammasome include the adaptor protein ASC (apoptosis‐associated speck‐like protein containing a CARD, also known as *PYCARD*, CARD5, TMS1, <http://www.uniprot.org/uniprot/Q9ULZ3>) and inflammatory caspases. The inflammasome activates the pro‐inflammatory cytokines <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4974> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5992](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5992), <http://www.uniprot.org/uniprot/P01584>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4983> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5986](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5986), <http://www.uniprot.org/uniprot/Q14116>) \[<http://www.ncbi.nlm.nih.gov/pubmed/25829385?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21219188?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1762><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1763><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1764><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1782><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1765><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1766><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1767>Common abbreviationNOD1NOD2----------HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16390](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16390), <http://www.uniprot.org/uniprot/Q9Y239>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5331](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5331), <http://www.uniprot.org/uniprot/Q9HC29>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29889](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29889), <http://www.uniprot.org/uniprot/Q7RTR2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16412](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16412), <http://www.uniprot.org/uniprot/Q9NPP4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29933](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29933), <http://www.uniprot.org/uniprot/Q86WI3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29890](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29890), <http://www.uniprot.org/uniprot/Q86UT6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7067](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7067), <http://www.uniprot.org/uniprot/P33076>Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5021><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5024>----------Comments--NOD2 has also been reported to be activated by ssRNA \[<http://www.ncbi.nlm.nih.gov/pubmed/19701189?dopt=AbstractPlus>\] although this has not been widely reproduced.--NLRC4 forms an inflammasome with the NAIP proteins following recognition of bacterial flagellin and type III secretion system rod proteins by the NAIPs.------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1768><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1769><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1770>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14374](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14374), <http://www.uniprot.org/uniprot/Q9C000>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22948](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22948), <http://www.uniprot.org/uniprot/Q9NX02>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16400](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16400), <http://www.uniprot.org/uniprot/Q96P20>Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8228> (pIC~50~ \> 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/25686105?dopt=AbstractPlus>\]Agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5024>----CommentsNLRP1 has 3 murine orthologues which lack the N‐terminal Pyrin domain. Murine NLRP1b ([http://www.ensembl.org/Mus_musculus/Gene/Summary?db=core;g=ENSMUSG00000070390;r=11:71153102‐71230733](http://www.ensembl.org/Mus_musculus/Gene/Summary?db=core;g=ENSMUSG00000070390;r=11:71153102‐71230733)) is the best characterised, responding to Anthrax Lethal Toxin.Along with NLRP7, NLRP2 is the product of a primate‐specific gene duplication.NLRP3 has been shown to be activated following disruption of cellular haemostasis by a wide‐variety of exogenous and endogenous molecules. The identity of the precise agonist that interacts with NLRP3 remains enigmatic. Efflux of potassium ions appears to be a common event for NLRP3 activating molecules. In addition to MCC950 \[<http://www.ncbi.nlm.nih.gov/pubmed/25686105?dopt=AbstractPlus>\] other small molecules including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10057> \[<http://www.ncbi.nlm.nih.gov/pubmed/29021150?dopt=AbstractPlus>\], β‐hydroxybutyrate \[<http://www.ncbi.nlm.nih.gov/pubmed/25686106?dopt=AbstractPlus>\], and various boron containing compounds \[<http://www.ncbi.nlm.nih.gov/pubmed/28943355?dopt=AbstractPlus>\] modulate NLRP3.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1771><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1772><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1773><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1774><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1775><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1776>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22943](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22943), <http://www.uniprot.org/uniprot/Q96MN2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21269](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21269), <http://www.uniprot.org/uniprot/P59047>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22944](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22944), <http://www.uniprot.org/uniprot/P59044>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22947](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22947), <http://www.uniprot.org/uniprot/Q8WX94>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22940](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22940), <http://www.uniprot.org/uniprot/Q86W28>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22941](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22941), <http://www.uniprot.org/uniprot/Q7RTR0>CommentsExpanded in the mouse resulting in 7 orthologues.----Absent in mouse. Along with NLRP2 the product of a primate‐specific gene duplication.Absent in mouseThis receptor has three murine orthologues.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1777><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1778><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1779><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1780><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1781>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21464](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21464), <http://www.uniprot.org/uniprot/Q86W26>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22945](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22945), <http://www.uniprot.org/uniprot/P59045>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22938](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22938), <http://www.uniprot.org/uniprot/P59046>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22937](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22937), <http://www.uniprot.org/uniprot/Q86W25>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:22939](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:22939), <http://www.uniprot.org/uniprot/Q86W24>CommentsNLRP10 lacks the LRR region.Absent in mouse--Absent in mouse--

Comments {#bph14751-sec-056}
--------

NLRP3 has also been reported to respond to hostderived products, known as danger‐associated molecular patterns, or DAMPs, including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4731> \[<http://www.ncbi.nlm.nih.gov/pubmed/16407889?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4719>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4954> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4865> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:620](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:620), <http://www.uniprot.org/uniprot/P05067>) \[<http://www.ncbi.nlm.nih.gov/pubmed/20303873?dopt=AbstractPlus>\].

Loss‐of‐function mutations of NLRP3 are associated with cold autoinflammatory and Muckle‐Wells syndromes.

This family also includes <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2793> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7634](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7634), <http://www.uniprot.org/uniprot/Q13075>) which can be found in the 'Inhibitors of apoptosis (IAP) protein family' in the <http://www.guidetopharmacology.org/GRAC/ReceptorFamiliesForward?type=OTHER> section of the Guide.

Further reading on NOD‐like receptor family {#bph14751-sec-057}
-------------------------------------------

Broz P *et al*. (2016) Inflammasomes: mechanism of assembly, regulation and signalling. *Nat. Rev. Immunol*. **16**: 407‐20 <https://www.ncbi.nlm.nih.gov/pubmed/27291964?dopt=AbstractPlus>

Bryant CE *et al*. (2015) International Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and disease. *Pharmacol. Rev*. **67**: 462‐504 <https://www.ncbi.nlm.nih.gov/pubmed/25829385?dopt=AbstractPlus>

Keestra‐Gounder AM *et al*. (2017) NOD1 and NOD2: Beyond Peptidoglycan Sensing. *Trends Immunol*. **38**: 758‐767 <https://www.ncbi.nlm.nih.gov/pubmed/28823510?dopt=AbstractPlus>

Lei‐Leston AC *et al*. (2017) Epithelial Cell Inflammasomes in Intestinal Immunity and Inflammation. *Front Immunol* **8**: 1168 <https://www.ncbi.nlm.nih.gov/pubmed/28979266?dopt=AbstractPlus>

Man SM. (2018) Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis. *Nat Rev Gastroenterol Hepatol* **15**: 721‐737 <https://www.ncbi.nlm.nih.gov/pubmed/30185915?dopt=AbstractPlus>

Mukherjee T *et al*. (2018) NOD1 and NOD2 in inflammation, immunity and disease. *Arch. Biochem. Biophys*. <https://www.ncbi.nlm.nih.gov/pubmed/30578751?dopt=AbstractPlus>

Nielsen AE *et al*. (2017) Synthetic agonists of NOD‐like, RIG‐I‐like, and C‐type lectin receptors for probing the inflammatory immune response. *Future Med Chem* **9**: 1345‐1360 <https://www.ncbi.nlm.nih.gov/pubmed/28776416?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=940> {#bph14751-sec-058}
===========================================================================

Overview {#bph14751-sec-059}
--------

There are three human RIG‐I‐like receptors (RLRs) which are cytoplasmic pattern recognition receptors (PRRs) of the innate immune system. They detect non‐self cytosolic double‐stranded RNA species and and 5′‐triphosphate single‐stranded RNA from various sources and are essential for inducing production of type I interferons, such as IFNβ, type III interferons, and other anti‐pathogenic effectors \[<http://www.ncbi.nlm.nih.gov/pubmed/25081315?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25829385?dopt=AbstractPlus>\]. They function as RNA helicases (EC 3.6.4.13) using the energy from ATP hydrolysis to unwind RNA.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2920><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2921><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2922>Common abbreviationRIG‐1MDA5LGP2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19102](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19102), <http://www.uniprot.org/uniprot/O95786>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18873](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18873), <http://www.uniprot.org/uniprot/Q9BYX4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29517](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29517), <http://www.uniprot.org/uniprot/Q96C10>

Further reading on RIG‐I‐like receptor family {#bph14751-sec-060}
---------------------------------------------

Chow KT *et al*. (2018) RIG‐I and Other RNA Sensors in Antiviral Immunity. *Annu. Rev. Immunol*. **36**: 667--694 <https://www.ncbi.nlm.nih.gov/pubmed/29677479?dopt=AbstractPlus>

Kato H *et al*. (2015) RIG‐I‐like receptors and autoimmune diseases. *Curr. Opin. Immunol*. **37**: 40--5 <https://www.ncbi.nlm.nih.gov/pubmed/26530735?dopt=AbstractPlus>

Lässig C *et al*. (2017) Discrimination of cytosolic self and non‐self RNA by RIG‐I‐like receptors. *J. Biol. Chem*. **292**: 9000‐9009 <https://www.ncbi.nlm.nih.gov/pubmed/28411239?dopt=AbstractPlus>

Ma Z *et al*. (2018) Innate Sensing of DNA Virus Genomes. *Annu Rev Virol* **5**: 341--362 <https://www.ncbi.nlm.nih.gov/pubmed/30265633?dopt=AbstractPlus>

Against Emerging and Re‐Emerging Viral Infections. *Front Immunol* **9**: 1379 <https://www.ncbi.nlm.nih.gov/pubmed/29973930?dopt=AbstractPlus>

Further reading on Pattern recognition receptors {#bph14751-sec-061}
------------------------------------------------

Broz P *et al*. (2016) Inflammasomes: mechanism of assembly, regulation and signalling. *Nat. Rev. Immunol*. **16**: 407--20 <https://www.ncbi.nlm.nih.gov/pubmed/27291964?dopt=AbstractPlus>

Bryant CE *et al*. (2015) Advances in Toll‐like receptor biology: Modes of activation by diverse stimuli. *Crit. Rev. Biochem. Mol. Biol*. **50**: 359--79 <https://www.ncbi.nlm.nih.gov/pubmed/25857820?dopt=AbstractPlus>

Feerick CL *et al*. (2017) Understanding the regulation of pattern recognition receptors in inflammatory diseases ‐ a 'Nod' in the right direction. *Immunology* **150**: 237--247 <https://www.ncbi.nlm.nih.gov/pubmed/27706808?dopt=AbstractPlus>

Rathinam VA *et al*. (2016) Inflammasome Complexes: Emerging Mechanisms and Effector Functions. *Cell* **165**: 792--800 <https://www.ncbi.nlm.nih.gov/pubmed/27153493?dopt=AbstractPlus>

Unterholzner L. (2013) The interferon response to intracellular DNA: why so many receptors? *Immunobiology* **218**: 1312--21 <https://www.ncbi.nlm.nih.gov/pubmed/23962476?dopt=AbstractPlus>

Yin Q *et al*. (2015) Structural biology of innate immunity. *Annu. Rev. Immunol*. **33**: 393--416 <https://www.ncbi.nlm.nih.gov/pubmed/25622194?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1022> {#bph14751-sec-062}
============================================================================

Overview {#bph14751-sec-063}
--------

The mammalian genome encodes transmembrane and soluble receptor guanylyl cyclases, both of which have enzyme activities which convert <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1742> to the intracellular second messenger cyclic guanosine‐3′,5′‐monophosphate (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347>).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=662> {#bph14751-sec-064}
===========================================================================

Overview {#bph14751-sec-065}
--------

Transmembrane guanylyl cyclases are homodimeric receptors activated by a diverse range of endogenous ligands. GC‐A, GC‐B and GC‐C are expressed predominantly in the cardiovascular system, skeletal system and intestinal epithelium, respectively. GC‐D and GC‐G are found in the olfactory neuropepithelium and Grüeneberg ganglion of rodents, respectively. GC‐E and GC‐F are expressed in retinal photoreceptors. Family members have conserved ligand‐binding, catalytic (guanylyl cyclase) and regulatory domains with the exception of NPR‐C which has an extracellular binding domain homologous to that of other NPRs, but with a truncated intracellular domain which appears to couple, *via* the G~i/o~ family of Gproteins, to activation of phospholipase C, inwardly‐rectifying potassium channels and inhibition of adenylyl cyclase activity \[<http://www.ncbi.nlm.nih.gov/pubmed/10364194?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1747><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1748><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1750><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1749>Common abbreviationGC‐AGC‐BGC‐CNPR‐CHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7943](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7943), <http://www.uniprot.org/uniprot/P16066>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7944](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7944), <http://www.uniprot.org/uniprot/P20594>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4688](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4688), <http://www.uniprot.org/uniprot/P25092>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7945](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7945), <http://www.uniprot.org/uniprot/P17342>Potency order<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4869> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7939](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7939), <http://www.uniprot.org/uniprot/P01160>) = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4890> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7940](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7940), <http://www.uniprot.org/uniprot/P16860>) ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4896> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7941](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7941), <http://www.uniprot.org/uniprot/P23582>) \[<http://www.ncbi.nlm.nih.gov/pubmed/1309330?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4896> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7941](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7941), <http://www.uniprot.org/uniprot/P23582>) ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4869> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7939](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7939), <http://www.uniprot.org/uniprot/P01160>) ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4890> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7940](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7940), <http://www.uniprot.org/uniprot/P16860>) \[<http://www.ncbi.nlm.nih.gov/pubmed/1309330?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5084> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4683](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4683), <http://www.uniprot.org/uniprot/Q16661>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4945> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4682](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4682), <http://www.uniprot.org/uniprot/Q02747>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4869> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7939](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7939), <http://www.uniprot.org/uniprot/P01160>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4896> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7941](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7941), <http://www.uniprot.org/uniprot/P23582>) ≥ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4890> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7940](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7940), <http://www.uniprot.org/uniprot/P16860>) \[<http://www.ncbi.nlm.nih.gov/pubmed/1309330?dopt=AbstractPlus>\]Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4869> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7939](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7939), <http://www.uniprot.org/uniprot/P01160>) (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/8700153?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4890> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7940](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7940), <http://www.uniprot.org/uniprot/P16860>) (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/8700153?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10211> \[<http://www.ncbi.nlm.nih.gov/pubmed/19729120?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4896> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7941](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7941), <http://www.uniprot.org/uniprot/P23582>) (Binding) \[<http://www.ncbi.nlm.nih.gov/pubmed/1309330?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4945> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4682](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4682), <http://www.uniprot.org/uniprot/Q02747>) (Binding), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5084> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4683](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4683), <http://www.uniprot.org/uniprot/Q16661>) (Binding)--Selective agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9070> \[<http://www.ncbi.nlm.nih.gov/pubmed/16778132?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9067> \[<http://www.ncbi.nlm.nih.gov/pubmed/23154072?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9066> \[<http://www.ncbi.nlm.nih.gov/pubmed/23272242?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5053> \[<http://www.ncbi.nlm.nih.gov/pubmed/8700153?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9066> \[<http://www.ncbi.nlm.nih.gov/pubmed/23272242?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9068> \[<http://www.ncbi.nlm.nih.gov/pubmed/23200862?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5017> \[<http://www.ncbi.nlm.nih.gov/pubmed/20863829?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17694454?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4854> \[<http://www.ncbi.nlm.nih.gov/pubmed/20863829?dopt=AbstractPlus>\], plecanatide \[195\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4892> \[<http://www.ncbi.nlm.nih.gov/pubmed/2823385?dopt=AbstractPlus>\]Endogenous antagonists------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5036> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29961](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29961), <http://www.uniprot.org/uniprot/P61366>) \[<http://www.ncbi.nlm.nih.gov/pubmed/17951249?dopt=AbstractPlus>\]Selective antagonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4856> (p*K* ~i~ 9.2--9.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/1680722?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4852> (p*K* ~i~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/2542088?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4952> \[<http://www.ncbi.nlm.nih.gov/pubmed/1674870?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4866> \[<http://www.ncbi.nlm.nih.gov/pubmed/1849131?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1826288?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9163> (p*K* ~d~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/15652659?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4952> \[<http://www.ncbi.nlm.nih.gov/pubmed/1674870?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4853> \[<http://www.ncbi.nlm.nih.gov/pubmed/15652659?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9162> \[<http://www.ncbi.nlm.nih.gov/pubmed/24297249?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4870> (Binding) (p*K* ~i~ 9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/10987424?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5020> \[<http://www.ncbi.nlm.nih.gov/pubmed/15337698?dopt=AbstractPlus>\]Labelled ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4845> (Agonist)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4847><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4850> (Agonist) \[<http://www.ncbi.nlm.nih.gov/pubmed/9122260?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4845>

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2898><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2031><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2899><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2900>Common abbreviationGC‐DGC‐EGC‐FGC‐GHGNC, UniProt--[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4689](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4689), <http://www.uniprot.org/uniprot/Q02846>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4691](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4691), <http://www.uniprot.org/uniprot/P51841>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:31863](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:31863), --Localisation--Retinal photoreceptorsRetinal photoreceptorsGrüneberg ganglionPrincipal function(s)--Vision/phototransductionVision/phototransductionThermosensationEndogenous ligands------ColdCommentsPseudogene in humans----Pseudogene in humans

Comments {#bph14751-sec-066}
--------

The polysaccharide obtained from fermentation of *Aureobasidium* species, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4952>, acts as an antagonist at both GC‐A and GC‐B receptor s \[<http://www.ncbi.nlm.nih.gov/pubmed/1674870?dopt=AbstractPlus>\]. GC‐D and GC‐G have been reported to be activated intracellularly by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9164> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4678](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4678), <http://www.uniprot.org/uniprot/P43080>) and guanylyl cyclaseactivating protein ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4679](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4679), <https://www.uniprot.org/uniprot/Q9UMX6>). GC‐D and GC‐G may be activated by atmospheric levels of CO~2~ through the formation of intracellular bicarbonate ions \[<http://www.ncbi.nlm.nih.gov/pubmed/20738256?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17702944?dopt=AbstractPlus>\]. GC‐G may be activated at cooler temperatures (20‐25°C) through apparent stabilisation of the dimer \[<http://www.ncbi.nlm.nih.gov/pubmed/25452496?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=939> {#bph14751-sec-067}
===========================================================================

Overview {#bph14751-sec-068}
--------

Nitric oxide (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509>)‐sensitive (soluble) guanylyl cyclase (GTP diphosphate‐lyase (cyclising)), [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=4.6.1.2](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=4.6.1.2), is a heterodimer comprising a β~1~ subunit and one of two alpha subunits (α~1~, α~2~) giving rise to two functionally indistinguishable isoforms, GC‐1 (α~1~β~1~) and GC‐2 (α~2~β~1~) \[<http://www.ncbi.nlm.nih.gov/pubmed/9742221?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9742212?dopt=AbstractPlus>\]. A haem group is associated with the β subunit and is the target for the endogenous ligand <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509>, and, potentially, carbon monoxide \[<http://www.ncbi.nlm.nih.gov/pubmed/9003762?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1287><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2897>Common abbreviationGC‐1GC‐2Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1290>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1288><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1290>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1289>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.2](http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.2](http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.2)Endogenous ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509>Selective activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9900> (pEC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/29643251?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5291> \[<http://www.ncbi.nlm.nih.gov/pubmed/9003762?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7527671?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9742221?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5168> \[apo‐GC‐1\] \[<http://www.ncbi.nlm.nih.gov/pubmed/12086987?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10213> \[<http://www.ncbi.nlm.nih.gov/pubmed/29859918?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5257> \[<http://www.ncbi.nlm.nih.gov/pubmed/11242081?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19089334?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5291> \[<http://www.ncbi.nlm.nih.gov/pubmed/7527671?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9742221?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5168> \[apo‐GC‐2\] \[<http://www.ncbi.nlm.nih.gov/pubmed/12086987?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10213> \[<http://www.ncbi.nlm.nih.gov/pubmed/29859918?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5257> \[<http://www.ncbi.nlm.nih.gov/pubmed/11242081?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19089334?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6554> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9489619?dopt=AbstractPlus>\] -- Bovine, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5234> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/7544433?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5234>

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1288><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1289><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1290><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1291>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4685](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4685), <http://www.uniprot.org/uniprot/Q02108>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4684](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4684), <http://www.uniprot.org/uniprot/P33402>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4687](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4687), <http://www.uniprot.org/uniprot/Q02153>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4686](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4686), <http://www.uniprot.org/uniprot/O75343>

Comments {#bph14751-sec-069}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5234> also shows activity at other haem‐containing proteins \[<http://www.ncbi.nlm.nih.gov/pubmed/10419542?dopt=AbstractPlus>\], while <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5291> may also inhibit cGMP‐hydrolysing phosphodiesterases \[<http://www.ncbi.nlm.nih.gov/pubmed/9855623?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10369473?dopt=AbstractPlus>\].

Further reading on Receptor guanylyl cyclase (RGC) family {#bph14751-sec-070}
---------------------------------------------------------

Kuhn M. (2016) Molecular Physiology of Membrane Guanylyl Cyclase Receptors. *Physiol. Rev*. **96**: 751‐804 <https://www.ncbi.nlm.nih.gov/pubmed/27030537?dopt=AbstractPlus>

Papapetropoulos A *et al*. (2015) Extending the translational potential of targeting NO/cGMP‐regulated pathways in the CVS. *Br. J. Pharmacol*. **172**: 1397--414 <https://www.ncbi.nlm.nih.gov/pubmed/25302549?dopt=AbstractPlus>

Santhekadur PK *et al*. (2017) The multifaceted role of natriuretic peptides in metabolic syndrome. *Biomed. Pharmacother*. **92**: 826--835 <https://www.ncbi.nlm.nih.gov/pubmed/28599248?dopt=AbstractPlus>

Vanhoutte PM *et al*. (2016) Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of the Endothelium‐Derived Vasodilator Mediator. *Circ. Res*. **119**: 375‐96 <https://www.ncbi.nlm.nih.gov/pubmed/27390338?dopt=AbstractPlus>

Volpe M *et al*. (2016) The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. *Clin. Sci*. **130**: 57--77 <https://www.ncbi.nlm.nih.gov/pubmed/26637405?dopt=AbstractPlus>

Waldman SA *et al*. (2018) Guanylate cyclase‐C as a therapeutic target in gastrointestinal disorders. *Gut* **67**: 1543--1552 <https://www.ncbi.nlm.nih.gov/pubmed/29563144?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304> {#bph14751-sec-071}
===========================================================================

Overview {#bph14751-sec-072}
--------

Receptor tyrosine kinases (RTKs), a family of cellsurface receptors, which transduce signals to polypeptide and protein hormones, cytokines and growth factors are key regulators of critical cellular processes, such as proliferation and differentiation, cell survival and metabolism, cell migration and cell cycle control \[<http://www.ncbi.nlm.nih.gov/pubmed/11357143?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17575237?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/2158859?dopt=AbstractPlus>\]. In the human genome, 58 RTKs have been identified, which fall into 20 families \[<http://www.ncbi.nlm.nih.gov/pubmed/20602996?dopt=AbstractPlus>\].

All RTKs display an extracellular ligand binding domain, a single transmembrane helix, a cytoplasmic region containing the protein tyrosine kinase activity (occasionally split into two domains by an insertion, termed the kinase insertion), with juxtamembrane and C‐terminal regulatory regions. Agonist binding to the extracellular domain evokes dimerization, and sometimes oligomerization, of RTKs (a small subset of RTKs forms multimers even in the absence of activating ligand). This leads to autophosphorylation in the tyrosine kinase domain in a trans orientation, serving as a site of assembly of protein complexes and stimulation of multiple signal transduction pathways, including <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244>, [http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=246\#mitogen‐activated protein kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=246#mitogen‐activatedproteinkinases) and phosphatidylinositol 3‐kinase \[<http://www.ncbi.nlm.nih.gov/pubmed/2158859?dopt=AbstractPlus>\].

RTKs are of widespread interest not only through physiological functions, but also as drug targets in many types of cancer and other disease states. Many diseases result from genetic changes or abnormalities that either alter the activity, abundance, cellular distribution and/or regulation of RTKs. Therefore, drugs thatmodify the dysregulated functions of these RTKs have been developed which fall into two categories. One group is often described as 'biologicals', which block the activation of RTKs directly or by chelating the cognate ligands, while the second are small molecules designed to inhibit the tyrosine kinase activity directly.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=320> {#bph14751-sec-073}
===========================================================================

Overview {#bph14751-sec-074}
--------

<http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00500000269785> are Class I receptor tyrosine kinases \[<http://www.ncbi.nlm.nih.gov/pubmed/12520021?dopt=AbstractPlus>\]. [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3430](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3430) (also known as HER‐2 or NEU) appears to act as an essential partner for the other members of the family without itself being activated by a cognate ligand \[<http://www.ncbi.nlm.nih.gov/pubmed/9130710?dopt=AbstractPlus>\]. Ligands of the ErbB family of receptors are peptides, many of which are generated by proteolytic cleavage of cell‐surface proteins. HER/ErbB is the viral counterpart to the receptor tyrosine kinase EGFR. All family members heterodimerize with each other to activate downstream signalling pathways and are aberrantly expressed inmany cancers, particularly forms of breast cancer and lung cancer. Mutations in the EGFR are responsible for acquired resistance to tyrosine kinase inhibitor chemotherapeutics.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2019><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1799>Common abbreviationEGFRHER2HER3HER4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3236](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3236), <http://www.uniprot.org/uniprot/P00533>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3430](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3430), <http://www.uniprot.org/uniprot/P04626>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3431](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3431), <http://www.uniprot.org/uniprot/P21860>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3432](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3432), <http://www.uniprot.org/uniprot/Q15303>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Endogenous ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4916> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4916>, <http://www.uniprot.org/uniprot/P01133>) (Binding), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4948> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3059](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3059), <http://www.uniprot.org/uniprot/Q99075>) (Binding), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5059> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11765](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11765), <http://www.uniprot.org/uniprot/P01135>) (Binding), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4864> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:651](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:651), <http://www.uniprot.org/uniprot/P15514>) (Binding), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4873> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1121](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1121), <http://www.uniprot.org/uniprot/P35070>) (Binding), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4917> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17470](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17470), <http://www.uniprot.org/uniprot/Q6UW88>) (Binding), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4918> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3443](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3443), <http://www.uniprot.org/uniprot/O14944>) (Binding)--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5027> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7997](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7997), <http://www.uniprot.org/uniprot/Q02297>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5029> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7998](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7998), <http://www.uniprot.org/uniprot/O14511>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4948> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3059](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3059), <http://www.uniprot.org/uniprot/Q99075>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4873> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1121](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1121), <http://www.uniprot.org/uniprot/P35070>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4918> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3443](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3443), <http://www.uniprot.org/uniprot/O14944>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5027> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7997](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7997), <http://www.uniprot.org/uniprot/Q02297>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5029> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7998](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7998), <http://www.uniprot.org/uniprot/O14511>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5030> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7999](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7999), <http://www.uniprot.org/uniprot/P56975>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5031> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29862](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29862), <http://www.uniprot.org/uniprot/Q8WWG1>)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5667> (p*K* ~d~ 9.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7944> (pIC~50~ 9.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17575237?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5667> (pIC~50~ 8--9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/20550212?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18408761?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7903> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/21306821?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7883> (pIC~50~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/18500794?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7944> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/17575237?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7879> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/20166197?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7903> (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/21306821?dopt=AbstractPlus>\]Antibodies<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8090> (Binding) (p*K* ~d~ 9.5) \[134\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6882> (Binding) (p*K* ~d~ 9.4) \[70\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5046> (Inhibition) (pIC~50~ \> 8) \[106\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5082> (Inhibition)----

Comments {#bph14751-sec-075}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4848> has been used to label the ErbB1 EGF receptor. The extracellular domain of ErbB2 can be targetted by the antibodies <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5082> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5046> to inhibit ErbB family action. The intracellular ATP‐binding site of the tyrosine kinase domain can be inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4947> (7.9‐8.0, \[<http://www.ncbi.nlm.nih.gov/pubmed/12639547?dopt=AbstractPlus>\]), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4941>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4920> and tyrphostins <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4863> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4862>.

Further reading on Type I RTKs: ErbB (epidermal growth factor) receptor family {#bph14751-sec-076}
------------------------------------------------------------------------------

Kobayashi Y *et al*. (2016) Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. *Cancer Sci*. **107**: 1179‐86 <https://www.ncbi.nlm.nih.gov/pubmed/27323238?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=321> {#bph14751-sec-077}
===========================================================================

Overview {#bph14751-sec-078}
--------

The circulating peptide hormones <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5012> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6081](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6081), <http://www.uniprot.org/uniprot/P01308>) and the related insulin‐like growth factors (IGF) activate Class II receptor tyrosine kinases \[<http://www.ncbi.nlm.nih.gov/pubmed/12520021?dopt=AbstractPlus>\], to evoke cellular responses, mediated through multiple intracellular adaptor proteins. Exceptionally amongst the catalytic receptors, the functional receptor in the insulin receptor family is derived from a single gene product, cleaved post‐translationally into two peptides, which then cross‐link via disulphide bridges to form a heterotetramer. Intriguingly, the endogenous peptide ligands are formed in a parallel fashion with post‐translational processing producing a heterodimer linked by disulphide bridges. Signalling through the receptors is mediated through a rapid autophosphorylation event at intracellular tyrosine residues, followed by recruitment of multiple adaptor proteins, notably [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6125](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6125) (<http://www.uniprot.org/uniprot/P35568>), [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6126](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6126) (<http://www.uniprot.org/uniprot/Q9Y4H2>), [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10840](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10840) (<http://www.uniprot.org/uniprot/P29353>), [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4566](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4566) (<http://www.uniprot.org/uniprot/P62993>) and [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11187](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11187) (<http://www.uniprot.org/uniprot/Q07889>).

Serum levels of free IGFs are kept low by the action of IGF binding proteins (IGFBP1‐5, <http://www.uniprot.org/uniprot/P08833>, <http://www.uniprot.org/uniprot/P18065>, <http://www.uniprot.org/uniprot/P17936>, <http://www.uniprot.org/uniprot/P22692>, <http://www.uniprot.org/uniprot/P24593>), which sequester the IGFs; overexpression of IGFBPs may induce apoptosis, while IGFBP levels are also altered in some cancers.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1801><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1802>Common abbreviationInsRIGF1RIRRHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6091](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6091), <http://www.uniprot.org/uniprot/P06213>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5465](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5465), <http://www.uniprot.org/uniprot/P08069>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6093](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6093), <http://www.uniprot.org/uniprot/P14616>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7952> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19778024?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5683> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19825801?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5683> (p*K* ~d~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5048> (pIC~50~ \> 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/16648580?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5912> (pIC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/9075698?dopt=AbstractPlus>\]--Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8067> (pIC~50~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/15050915?dopt=AbstractPlus>\]--Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5012> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6081](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6081), <http://www.uniprot.org/uniprot/P01308>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4971> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5464](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5464), <http://www.uniprot.org/uniprot/P05019>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4972> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5466](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5466), <http://www.uniprot.org/uniprot/P01344>)--

Comments {#bph14751-sec-079}
--------

There is evidence for low potency binding and activation of insulin receptors by IGF1. IGF2 also binds and activates the cation‐independent mannose 6‐phosphate receptor (also known as the insulin‐like growth factor 2 receptor; [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5467](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5467); <http://www.uniprot.org/uniprot/P11717>), which lacks classical signalling capacity and appears to subserve a trafficking role \[<http://www.ncbi.nlm.nih.gov/pubmed/2964083?dopt=AbstractPlus>\]. INSRR, which has a much more discrete localization, being predominant in the kidney \[<http://www.ncbi.nlm.nih.gov/pubmed/1530648?dopt=AbstractPlus>\], currently lacks a cognate ligand or evidence for functional impact. Antibodies targetting IGF1, IGF2 and the extracellular portion of the IGF1 receptor are in clinical trials.

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5048> inhibits the insulin‐like growth factor receptor \[5\], while BMS‐536924 inhibits both the insulin receptor and the insulinlike growth factor receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/16134929?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=322> {#bph14751-sec-080}
===========================================================================

Overview {#bph14751-sec-081}
--------

Type III RTKs include PDGFR, CSF‐1R (Ems), Kit and FLT3, which function as homo‐ or heterodimers. Endogenous ligands of PDGF receptors are homo‐ or heterodimeric: PDGFA, PDGFB, VEGFE and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5323> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30620](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30620), <http://www.uniprot.org/uniprot/Q9GZP0>) combine as homo‐ or heterodimers to activate homo‐ or heterodimeric PDGF receptors. SCF is a dimeric ligand for KIT. Ligands for CSF1R are either monomeric or dimeric glycoproteins, while the endogenous agonist for FLT3 is a homodimer.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1803><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1804><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1805>Common abbreviationPDGFRαPDGFRβKitHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8803](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8803), <http://www.uniprot.org/uniprot/P16234>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8804](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8804), <http://www.uniprot.org/uniprot/P09619>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6342](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6342), <http://www.uniprot.org/uniprot/P10721>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Endogenous ligandsPDGFPDGF--Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7882> (p*K* ~d~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/22745105?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7885> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19320489?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7882> (p*K* ~d~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22745105?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5712> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/16891463?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7886> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/21028894?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5713> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/23279183?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5713> (p*K* ~i~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/12538485?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5713> (p*K* ~d~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7886> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/21028894?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5656> (p*K* ~d~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5712> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/16891463?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7969> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22864397?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5711> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/15466206?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8069> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/15705896?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8069> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/15705896?dopt=AbstractPlus>\]--Endogenous agonists----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5055> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6343](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6343), <http://www.uniprot.org/uniprot/P21583>) \[<http://www.ncbi.nlm.nih.gov/pubmed/7536489?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1806><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807>Common abbreviationCSFRFLT3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2433](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2433), <http://www.uniprot.org/uniprot/P07333>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3765](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3765), <http://www.uniprot.org/uniprot/P36888>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Endogenous ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4934> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2438](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2438), <http://www.uniprot.org/uniprot/P09919>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4942> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2434](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2434), <http://www.uniprot.org/uniprot/P04141>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4905> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2432](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2432), <http://www.uniprot.org/uniprot/P09603>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4932> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3766](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3766), <http://www.uniprot.org/uniprot/P49771>)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5689> (pIC~50~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19887542?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5690> (p*K* ~d~ 9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5690> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/17121910?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5685> (p*K* ~d~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5689> (p*K* ~d~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8095> (p*K* ~d~ 9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/24900421?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657> (p*K* ~d~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7882> (p*K* ~d~ 9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22745105?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7885> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/19320489?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5695> (p*K* ~d~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5695> (pIC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/12124172?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5685> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/16249345?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8108> (pIC~50~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/24532805?dopt=AbstractPlus>\]CommentsUpregulation of CSF1R expression is associated with migroglial activation and immune pathology in Alzhermer&apos;s disease (AD) \[[71](#bph14751-bib-0071){ref-type="ref"}, <http://www.ncbi.nlm.nih.gov/pubmed/23392676?dopt=AbstractPlus>\]. Pharmacological inhibition of CSF1R with <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5685> reduces microglial proliferation and prevents disease progression in a mouse model of AD, but this does not correlate with amyloid‐β plaque numbers \[<http://www.ncbi.nlm.nih.gov/pubmed/26747862?dopt=AbstractPlus>\].<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4855> has been described as a selective FLT3 inhibitor \[<http://www.ncbi.nlm.nih.gov/pubmed/20153646?dopt=AbstractPlus>\].

Comments {#bph14751-sec-082}
--------

Various small molecular inhibitors of type III RTKs have been described, including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5697> (targetting PDGFR, KIT and CSF1R); <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5702> and AC220 (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5658>; FLT3), as well as pan‐type III RTK inhibitors such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5713> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5711> \[<http://www.ncbi.nlm.nih.gov/pubmed/15606337?dopt=AbstractPlus>\]; 5′‐fluoroindirubinoxime has been described as a selective FLT3 inhibitor \[2\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=324> {#bph14751-sec-083}
===========================================================================

Overview {#bph14751-sec-084}
--------

<http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00440000236870> are homo‐ and heterodimeric proteins, which are characterized by seven Ig‐like loops in their extracellular domains and a split kinase domain in the cytoplasmic region. They are key regulators of angiogenesis and lymphangiogenesis; as such, they have been the focus of drug discovery for conditions such as metastatic cancer. Splice variants of VEGFR1 and VEGFR2 generate truncated proteins limited to the extracellular domains, capable of homodimerisation and binding VEGF ligands as a soluble, non‐signalling entity. Ligands at VEGF receptors are typically homodimeric. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5085> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12680](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12680), <http://www.uniprot.org/uniprot/P15692>) is able to activate VEGFR1 homodimers, VEGFR1/2 heterodimers and VEGFR2/3 heterodimers. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5086> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12681](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12681), <http://www.uniprot.org/uniprot/P49765>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5314> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8893](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8893), <http://www.uniprot.org/uniprot/P49763>) activate VEGFR1 homodimers, while VEGFC (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5087>, <http://www.uniprot.org/uniprot/P49767>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5088> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3708](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3708), <http://www.uniprot.org/uniprot/O43915>) activate VEGFR2/3 heterodimers and VEGFR3 homodimers, and, following proteolysis, VEGFR2 homodimers.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1812><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1814>Common abbreviationVEGFR‐1VEGFR‐2VEGFR‐3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3763](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3763), <http://www.uniprot.org/uniprot/P17948>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6307](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6307), <http://www.uniprot.org/uniprot/P35968>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3767](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3767), <http://www.uniprot.org/uniprot/P35916>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Endogenous ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5085> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5085>, <http://www.uniprot.org/uniprot/P15692>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5086> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5086>, <http://www.uniprot.org/uniprot/P49765>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5085> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5085>, <http://www.uniprot.org/uniprot/P15692>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5087> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5087>, <http://www.uniprot.org/uniprot/P49767>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5089> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8801](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8801), <http://www.uniprot.org/uniprot/Q9NRA1>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5087> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5087>, <http://www.uniprot.org/uniprot/P49767>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5088> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3708](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3708), <http://www.uniprot.org/uniprot/O43915>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5089> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8801](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8801), <http://www.uniprot.org/uniprot/Q9NRA1>)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5712> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16891463?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8189> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22148921?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5056> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/10882357?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5887> (pIC~50~ 10.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21926191?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5659> (pIC~50~ 9.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/20869793?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5679> (pIC~50~ 8.2--9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/23098265?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5664> (p*K* ~d~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7944> (pIC~50~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/17575237?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5660> (p*K* ~d~ 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7886> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/21028894?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5659> (p*K* ~d~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7944> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/17575237?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5713> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/20570526?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936> (pIC~50~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/18559524?dopt=AbstractPlus>\]Sub/family‐selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5698> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/18620382?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5698> (p*K* ~d~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5698> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18620382?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5698> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/18620382?dopt=AbstractPlus>\]Antibodies--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7390> (Antagonist) (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/12917408?dopt=AbstractPlus>\]--

Comments {#bph14751-sec-085}
--------

The VEGFR, as well as VEGF ligands, have been targeted by antibodies and tyrosine kinase inhibitors. DMH4 \[<http://www.ncbi.nlm.nih.gov/pubmed/12443771?dopt=AbstractPlus>\], Ki8751 \[<http://www.ncbi.nlm.nih.gov/pubmed/15743179?dopt=AbstractPlus>\] and ZM323881, a novel inhibitor of vascular endothelial growth factor‐receptor‐2 tyrosine kinase activity \[<http://www.ncbi.nlm.nih.gov/pubmed/12483548?dopt=AbstractPlus>\] are described as VEGFR2‐selective tyrosine kinase inhibitors. Bevacizumab is a monoclonal antibody directed against VEGF‐A, used clinically for the treatment of certain metastatic cancers; an antibody fragment has been used for wet age‐related macular degeneration.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=323> {#bph14751-sec-086}
===========================================================================

Overview {#bph14751-sec-087}
--------

Fibroblast growth factor (FGF) family receptors act as homo‐ and heterodimers, and are characterized by Ig‐like loops in the extracellular domain, in which disulphide bridges may form across protein partners to allow the formation of covalent dimers which may be constitutively active. FGF receptors have been implicated in achondroplasia, angiogenesis and numerous congenital disorders. At least 22 members of the FGF gene family have been identified in the human genome \[11\]. Within this group, subfamilies of FGF may be divided into canonical, intracellular and hormone‐like FGFs. FGF1‐FGF10 have been identified to act through FGF receptors, while FGF11‐14 appear to signal through intracellular targets. Other family members are less well characterized \[<http://www.ncbi.nlm.nih.gov/pubmed/21711248?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1809><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1810><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1811>Common abbreviationFGFR1FGFR2FGFR3FGFR4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3688](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3688), <http://www.uniprot.org/uniprot/P11362>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3689](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3689), <http://www.uniprot.org/uniprot/P21802>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3690](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3690), <http://www.uniprot.org/uniprot/P22607>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3691](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3691), <http://www.uniprot.org/uniprot/P22455>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Endogenous ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4923> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3665](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3665), <http://www.uniprot.org/uniprot/P05230>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4924> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3676](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3676), <http://www.uniprot.org/uniprot/P09038>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4925> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3682](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3682), <http://www.uniprot.org/uniprot/P08620>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4926> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3683](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3683), <http://www.uniprot.org/uniprot/P12034>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4927> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3684](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3684), <http://www.uniprot.org/uniprot/P10767>) \[<http://www.ncbi.nlm.nih.gov/pubmed/8663044?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4923> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3665](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3665), <http://www.uniprot.org/uniprot/P05230>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4925> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3682](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3682), <http://www.uniprot.org/uniprot/P08620>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4928> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3685](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3685), <http://www.uniprot.org/uniprot/P21781>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4930> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3687](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3687), <http://www.uniprot.org/uniprot/P31371>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4924> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3676](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3676), <http://www.uniprot.org/uniprot/P09038>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4927> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3684](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3684), <http://www.uniprot.org/uniprot/P10767>) \[<http://www.ncbi.nlm.nih.gov/pubmed/8663044?dopt=AbstractPlus>\] <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9641> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3666](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3666), <http://www.uniprot.org/uniprot/O15520>) \[<http://www.ncbi.nlm.nih.gov/pubmed/12591959?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4923> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3665](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3665), <http://www.uniprot.org/uniprot/P05230>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4924> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3676](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3676), <http://www.uniprot.org/uniprot/P09038>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4930> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3687](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3687), <http://www.uniprot.org/uniprot/P31371>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4925> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3682](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3682), <http://www.uniprot.org/uniprot/P08620>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4929> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3686](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3686), <http://www.uniprot.org/uniprot/P55075>) \[<http://www.ncbi.nlm.nih.gov/pubmed/8663044?dopt=AbstractPlus>\] <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9629> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3681](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3681), <http://www.uniprot.org/uniprot/P11487>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4923> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3665](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3665), <http://www.uniprot.org/uniprot/P05230>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4924> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3676](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3676), <http://www.uniprot.org/uniprot/P09038>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4925> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3682](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3682), <http://www.uniprot.org/uniprot/P08620>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4930> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3687](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3687), <http://www.uniprot.org/uniprot/P31371>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4927> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3684](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3684), <http://www.uniprot.org/uniprot/P10767>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4929> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3686](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3686), <http://www.uniprot.org/uniprot/P55075>) \[<http://www.ncbi.nlm.nih.gov/pubmed/8663044?dopt=AbstractPlus>\]Sub/family‐selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8104> (pIC~50~ 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/21900693?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8104> (pIC~50~ 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/21900693?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8104> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/21900693?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8104> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/21900693?dopt=AbstractPlus>\]Selective inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8862> (Irreversible inhibition) (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/25776529?dopt=AbstractPlus>\]Agonists--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6954>----

Comments {#bph14751-sec-088}
--------

Splice variation of the receptors can influence agonist responses. [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3693](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3693) (<http://www.uniprot.org/uniprot/Q8N441>) is a truncated kinase‐null analogue. Various antibodies and tyrosine kinase inhibitors have been developed against FGF receptors \[<http://www.ncbi.nlm.nih.gov/pubmed/22884522?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20338520?dopt=AbstractPlus>\]. PD161570 is an FGFR tyrosine kinase inhibitor \[<http://www.ncbi.nlm.nih.gov/pubmed/9488112?dopt=AbstractPlus>\], while <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5037> has been described to inhibit FGFR1 and FGFR3 \[<http://www.ncbi.nlm.nih.gov/pubmed/10987832?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=792> {#bph14751-sec-089}
===========================================================================

Overview {#bph14751-sec-090}
--------

The PTK7 receptor is associated with polarization of epithelial cells and the development of neural structures. Sequence analysis suggests that the gene product is catalytically inactive as a protein kinase, although there is evidence for a role in Wnt signalling \[<http://www.ncbi.nlm.nih.gov/pubmed/21132015?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1848>Common abbreviationCCK4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9618](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9618), <http://www.uniprot.org/uniprot/Q13308>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)

Comments {#bph14751-sec-091}
--------

Thus far, no selective PTK7 inhibitors have been described.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=326> {#bph14751-sec-092}
===========================================================================

Overview {#bph14751-sec-093}
--------

The neurotrophin receptor family of RTKs include trkA, trkB and trkC (tropomyosin‐related kinase) receptors, which respond to NGF, BDNF and neurotrophin‐3, respectively. They are associated primarily with proliferative and migration effects in neural systems. Various isoforms of neurotrophin receptors exist, including truncated forms of trkB and trkC, which lack catalytic domains. p75 (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=334#show_object_1888>, also known as nerve growth factor receptor), which has homologies with <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=334>, lacks a tyrosine kinase domain, but can signal via ceramide release and nuclear factor θB (NF‐θB) activation. Both trkA and trkB contain two leucine‐rich regions and can exist in monomeric or dimeric forms.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1817><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1818><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1819>Common abbreviationtrkAtrkBtrkCHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8031](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8031), <http://www.uniprot.org/uniprot/P04629>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8032](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8032), <http://www.uniprot.org/uniprot/Q16620>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8033](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8033), <http://www.uniprot.org/uniprot/Q16288>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Endogenous ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5026> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5026>, <http://www.uniprot.org/uniprot/P01138>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5033> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8023](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8023), <http://www.uniprot.org/uniprot/P20783>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4872> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4872>, <http://www.uniprot.org/uniprot/P23560>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5034> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8024](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8024), <http://www.uniprot.org/uniprot/P34130>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5033> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8023](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8023), <http://www.uniprot.org/uniprot/P20783>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5033> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8023](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8023), <http://www.uniprot.org/uniprot/P20783>)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10314> (pIC~50~ \>9.3) \[[165](#bph14751-bib-0165){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8138> (pIC~50~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/24900538?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7938> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/19603809?dopt=AbstractPlus>\]----Sub/family‐selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7700> (pIC~50~ \>8.3) \[[6](#bph14751-bib-0006){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8071> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/24900443?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7700> (pIC~50~ \>8.3) \[[6](#bph14751-bib-0006){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8071> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/24900443?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7700> (pIC~50~ \>8.3) \[[6](#bph14751-bib-0006){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8071> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/24900443?dopt=AbstractPlus>\]

Comments {#bph14751-sec-094}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4849> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4846> have been used to label the trkA and trkB receptor, respectively. p75 influences the binding of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5026> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5026>, <http://www.uniprot.org/uniprot/P01138>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5033> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8023](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8023), <http://www.uniprot.org/uniprot/P20783>) to trkA. The ligand selectivity of p75 appears to be dependent on the cell type; for example, in sympathetic neurones, it binds <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5033> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8023](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8023), <http://www.uniprot.org/uniprot/P20783>) with comparable affinity to trkC \[<http://www.ncbi.nlm.nih.gov/pubmed/9204912?dopt=AbstractPlus>\].

Small molecule agonists of trkB have been described, including LM22A4 \[<http://www.ncbi.nlm.nih.gov/pubmed/20407211?dopt=AbstractPlus>\], while ANA12 has been described as a noncompetitive antagonist of BDNF binding to trkB \[<http://www.ncbi.nlm.nih.gov/pubmed/21505263?dopt=AbstractPlus>\]. GNF5837 is a family‐selective tyrosine kinase inhibitor \[<http://www.ncbi.nlm.nih.gov/pubmed/24900443?dopt=AbstractPlus>\], while the tyrosine kinase activity of the trkA receptor can be inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4946> (pIC~50~= 8.7, \[<http://www.ncbi.nlm.nih.gov/pubmed/15013000?dopt=AbstractPlus>\]) and tyrphostin <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4863> \[<http://www.ncbi.nlm.nih.gov/pubmed/7683492?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=332> {#bph14751-sec-095}
===========================================================================

Overview {#bph14751-sec-096}
--------

Members of the ROR family appear to be activated by ligands complexing with other cell‐surface proteins. Thus, ROR1 and ROR2 appear to be activated by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3548> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12784](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12784), <http://www.uniprot.org/uniprot/P41221>) binding to a <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=25> thereby forming a cell‐surface multiprotein complex \[<http://www.ncbi.nlm.nih.gov/pubmed/21078818?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1845><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1846>Common abbreviationROR1ROR2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10256](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10256), <http://www.uniprot.org/uniprot/Q01973>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10257](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10257), <http://www.uniprot.org/uniprot/Q01974>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=793> {#bph14751-sec-097}
===========================================================================

Overview {#bph14751-sec-098}
--------

The muscle‐specific kinase MuSK is associated with the formation and organisation of the neuromuscular junction from the skeletal muscle side. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5319> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:329](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:329), <http://www.uniprot.org/uniprot/O00468>) forms a complex with <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5320> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6696](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6696), <http://www.uniprot.org/uniprot/O75096>) to activate MuSK \[<http://www.ncbi.nlm.nih.gov/pubmed/18848351?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1847>Common abbreviationMuSKHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7525](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7525), <http://www.uniprot.org/uniprot/O15146>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)

Comments {#bph14751-sec-099}
--------

Thus far, no selective MuSK inhibitors have been described.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=325> {#bph14751-sec-100}
===========================================================================

Overview {#bph14751-sec-101}
--------

HGF receptors regulatematuration of the liver in the embryo, as well as having roles in the adult, for example, in the innate immune system. HGF is synthesized as a single gene product, which is post‐translationally processed to yield a heterodimer linked by a disulphide bridge. The maturation of HGF is enhanced by a serine protease, HGF activating complex, and inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5315> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11246](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11246), <http://www.uniprot.org/uniprot/O43278>), a serine protease inhibitor. MST1, the ligand of RON, is two disulphide‐linked peptide chains generated by proteolysis of a single gene product.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1816>Common abbreviationMETRonHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7029](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7029), <http://www.uniprot.org/uniprot/P08581>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7381](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7381), <http://www.uniprot.org/uniprot/Q04912>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Endogenous ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4949> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4893](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4893), <http://www.uniprot.org/uniprot/P14210>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5023> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7380](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7380), <http://www.uniprot.org/uniprot/P09603>)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7904> (pIC~50~ 9.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/21918175?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5709> (p*K* ~d~ 9.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5887> (pIC~50~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/21926191?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7953> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19260711?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5709> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/19934279?dopt=AbstractPlus>\]--

Comments {#bph14751-sec-102}
--------

PF04217903 is a selective Met tyrosine kinase inhibitor \[<http://www.ncbi.nlm.nih.gov/pubmed/22924734?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5057> is an inhibitor of the HGF receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/14500382?dopt=AbstractPlus>\], with the possibility of further targets \[<http://www.ncbi.nlm.nih.gov/pubmed/17595299?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=328> {#bph14751-sec-103}
===========================================================================

Overview {#bph14751-sec-104}
--------

Members of this RTK family represented a novel structural motif, when sequenced. The ligands for this family, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4935> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4168](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4168), <http://www.uniprot.org/uniprot/Q14393>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5050> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9456](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9456), <http://www.uniprot.org/uniprot/P07225>), are secreted plasma proteins which undergo vitamin K‐dependent post‐translational modifications generating carboxyglutamate‐rich domains which are able to bind to negatively‐charged surfaces of apoptotic cells.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1835><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1836><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1837>Common abbreviationAxlTyro3MerHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:905](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:905), <http://www.uniprot.org/uniprot/P30530>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12446](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12446), <http://www.uniprot.org/uniprot/Q06418>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7027](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7027), <http://www.uniprot.org/uniprot/Q12866>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Endogenous ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4935> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4168](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4168), <http://www.uniprot.org/uniprot/Q14393>) \[<http://www.ncbi.nlm.nih.gov/pubmed/8939948?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5050> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9456](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9456), <http://www.uniprot.org/uniprot/P07225>) \[<http://www.ncbi.nlm.nih.gov/pubmed/7867073?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4935> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4168](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4168), <http://www.uniprot.org/uniprot/Q14393>) \[<http://www.ncbi.nlm.nih.gov/pubmed/8939948?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5050> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9456](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9456), <http://www.uniprot.org/uniprot/P07225>) \[<http://www.ncbi.nlm.nih.gov/pubmed/7867073?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4935> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4168](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4168), <http://www.uniprot.org/uniprot/Q14393>) \[<http://www.ncbi.nlm.nih.gov/pubmed/8939948?dopt=AbstractPlus>\]

Comments {#bph14751-sec-105}
--------

AXL tyrosine kinase inhibitors have been described \[<http://www.ncbi.nlm.nih.gov/pubmed/22247788?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=330> {#bph14751-sec-106}
===========================================================================

Overview {#bph14751-sec-107}
--------

The TIE family were initially associated with formation of blood vessels. Endogenous ligands are <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4867> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:484](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:484), <http://www.uniprot.org/uniprot/Q15389>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5316> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:485](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:485), <http://www.uniprot.org/uniprot/O15123>), and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4868> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:487](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:487), <http://www.uniprot.org/uniprot/Q9Y264>). <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5316> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:485](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:485), <http://www.uniprot.org/uniprot/O15123>) appears to act as an endogenous antagonist of angiopoietin‐1 function.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1841><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1842>Common abbreviationTIE1TIE2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11809](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11809), <http://www.uniprot.org/uniprot/P35590>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11724](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11724), <http://www.uniprot.org/uniprot/Q02763>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Endogenous ligands--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4867> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:484](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:484), <http://www.uniprot.org/uniprot/Q15389>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4868> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:487](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:487), <http://www.uniprot.org/uniprot/Q9Y264>)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=327> {#bph14751-sec-108}
===========================================================================

Overview {#bph14751-sec-109}
--------

Ephrin receptors are a family of 15 RTKs (the largest family of RTKs) with two identified subfamilies (EphA and EphB), which have a role in the regulation of neuronal development, cell migration, patterning and angiogenesis. Their ligands are membrane‐associated proteins, thought to be glycosylphosphatidylinositol‐linked for EphA (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4908> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3221](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3221), <http://www.uniprot.org/uniprot/P20827>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4909> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3222](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3222), <http://www.uniprot.org/uniprot/O43921>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4910> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3223](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3223), <http://www.uniprot.org/uniprot/P52797>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4911> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3224](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3224), <http://www.uniprot.org/uniprot/P52798>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4912> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3225](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3225), <http://www.uniprot.org/uniprot/P52803>)) and 1TM proteins for Ephrin B (<http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000002014>: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4913> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3226](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3226), <http://www.uniprot.org/uniprot/P98172>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4914> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3227](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3227), <http://www.uniprot.org/uniprot/P52799>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4915> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3228](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3228), <http://www.uniprot.org/uniprot/Q15768>)), although the relationship between ligands and receptors has been incompletely defined.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1821><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1822><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1823><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1824><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1825><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1826><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1827>Common abbreviationEphA1EphA2EphA3EphA4EphA5EphA6EphA7HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3385](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3385), <http://www.uniprot.org/uniprot/P21709>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3386](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3386), <http://www.uniprot.org/uniprot/P29317>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3387](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3387), <http://www.uniprot.org/uniprot/P29320>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3388](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3388), <http://www.uniprot.org/uniprot/P54764>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3389](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3389), <http://www.uniprot.org/uniprot/P54756>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19296](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19296), <http://www.uniprot.org/uniprot/Q9UF33>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3390](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3390), <http://www.uniprot.org/uniprot/Q15375>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1828><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1829><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1830><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1831><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1832><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1833><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1834>Common abbreviationEphA8EphA10EphB1EphB2EphB3EphB4EphB6HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3391](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3391), <http://www.uniprot.org/uniprot/P29322>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19987](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19987), <http://www.uniprot.org/uniprot/Q5JZY3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3392](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3392), <http://www.uniprot.org/uniprot/P54762>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3393](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3393), <http://www.uniprot.org/uniprot/P29323>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3394](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3394), <http://www.uniprot.org/uniprot/P54753>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3395](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3395), <http://www.uniprot.org/uniprot/P54760>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3396](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3396), <http://www.uniprot.org/uniprot/O15197>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8141> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/19788238?dopt=AbstractPlus>\]----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7944> (pIC~50~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/17575237?dopt=AbstractPlus>\]--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=794> {#bph14751-sec-110}
===========================================================================

Overview {#bph14751-sec-111}
--------

Ret proto‐oncogene (Rearranged during transfection) is a transmembrane tyrosine kinase enzyme which is employed as a signalling partner for members of the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=314>. Ligand‐activated GFR appears to recruit Ret as a dimer, leading to activation of further intracellular signalling pathways. Ret appears to be involved in neural crest development, while mutations may be involved in multiple endocrine neoplasia, Hirschsprung&apos;s disease, and medullary thyroid carcinoma.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2185>Common abbreviationRetHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9967](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9967), <http://www.uniprot.org/uniprot/P07949>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5706> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/19107952?dopt=AbstractPlus>\]

Comments {#bph14751-sec-112}
--------

A number of tyrosine kinase inhibitors targeting RET have been described \[<http://www.ncbi.nlm.nih.gov/pubmed/21960212?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=795> {#bph14751-sec-113}
===========================================================================

Overview {#bph14751-sec-114}
--------

The 'related to tyrosine kinase receptor' (Ryk) is structurally atypical of the family of RTKs, particularly in the activation and ATP‐binding domains. RYK has been suggested to lack kinase activity and appears to be involved, with FZD8, in the Wnt signalling system \[<http://www.ncbi.nlm.nih.gov/pubmed/21132015?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1849>Common abbreviationRYKHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10481](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10481), <http://www.uniprot.org/uniprot/P34925>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)

Comments {#bph14751-sec-115}
--------

Thus far, no selective RYK inhibitors have been described.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=331> {#bph14751-sec-116}
===========================================================================

Overview {#bph14751-sec-117}
--------

Discoidin domain receptors 1 and 2 (DDR1 and DDR2) are structurally‐related membrane protein tyrosine kinases activated by collagen. Collagen is probably the most abundant protein in man, with at least 29 families of genes encoding proteins, which undergo splice variation and post‐translational processing, and may exist in monomeric or polymeric forms, producing a triple‐stranded, twine‐like structure. In man, principal family members include <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4898> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2197](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2197), <http://www.uniprot.org/uniprot/P02452>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4899> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2200](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2200), <http://www.uniprot.org/uniprot/P02458>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4900> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2201](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2201), <http://www.uniprot.org/uniprot/P02461>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4901> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2202](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2202), <http://www.uniprot.org/uniprot/P02462>).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1843><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1844>Common abbreviationDDR1DDR2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2730](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2730), <http://www.uniprot.org/uniprot/Q08345>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2731](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2731), <http://www.uniprot.org/uniprot/Q16832>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)

Comments {#bph14751-sec-118}
--------

The tyrosine kinase inhibitors of DDR, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5697>, were identified from proteomic analysis \[<http://www.ncbi.nlm.nih.gov/pubmed/18938156?dopt=AbstractPlus>\]. Other collagen receptors include glycoprotein VI (<http://www.uniprot.org/uniprot/Q9HCN6>), leukocyte‐associated immunoglobulin‐like receptor 1 (<http://www.uniprot.org/uniprot/Q6GTX8>), leukocyte‐associated immunoglobulin‐like receptor 2 (<http://www.uniprot.org/uniprot/Q6ISS4>) and osteoclast‐associated immunoglobulin‐like receptor (<http://www.uniprot.org/uniprot/Q8IYS5>).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=796> {#bph14751-sec-119}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1840>Common abbreviationROSHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10261](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10261), <http://www.uniprot.org/uniprot/P08922>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)

Comments {#bph14751-sec-120}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4903> is a tyrosine kinase inhibitor, anti‐cancer drug targeting ALK and ROS1.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=658> {#bph14751-sec-121}
===========================================================================

Overview {#bph14751-sec-122}
--------

The LMR kinases are unusual amongst the RTKs in possessing a short extracellular domain and extended intracellular domain (hence the 'Lemur' name reflecting the long tail). A precise function for these receptors has yet to be defined, although LMR1 was identified as a potential marker of apoptosis \[<http://www.ncbi.nlm.nih.gov/pubmed/9444961?dopt=AbstractPlus>\], giving rise to the name AATYK (Apoptosis‐associated tyrosine kinase); while over‐expression induces differentiation in neuroblastoma cells \[<http://www.ncbi.nlm.nih.gov/pubmed/10837911?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1922><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2056><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2057>Common abbreviationLmr1Lmr2Lmr3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21), <http://www.uniprot.org/uniprot/Q6ZMQ8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17880](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17880), <http://www.uniprot.org/uniprot/Q8IWU2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19295](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19295), <http://www.uniprot.org/uniprot/Q96Q04>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1)

Comments {#bph14751-sec-123}
--------

As yet no selective inhibitors of the LMR family have been described.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=329> {#bph14751-sec-124}
===========================================================================

Overview {#bph14751-sec-125}
--------

The LTK family appear to lack endogenous ligands. LTK is subject to tissue‐specific splice variation, which appears to generate products in distinct subcellular locations. ALK fusions created by gene translocations and rearrangements are associated with many types of cancer, including large cell lymphomas, inflammatory myofibrilastic tumours and non‐small cell lung cancer \[<http://www.ncbi.nlm.nih.gov/pubmed/23742252?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1838><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1839>Common abbreviationLTKALKHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6721](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6721), <http://www.uniprot.org/uniprot/P29376>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:427](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:427), <http://www.uniprot.org/uniprot/Q9UM73>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.1)Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5683> (pIC~50~ 9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/19825801?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8137> (pIC~50~ 9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/24432909?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4903> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/21812414?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5714> (p*K* ~d~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8139> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/22564207?dopt=AbstractPlus>\] <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397> (pIC~50~ 9.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/23742252?dopt=AbstractPlus>\]Selective inhibitors----Comments--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4903> appears to be a selective ALK inhibitor acting on the tyrosine kinase activity \[<http://www.ncbi.nlm.nih.gov/pubmed/21156280?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=668> {#bph14751-sec-126}
===========================================================================

Overview {#bph14751-sec-127}
--------

Similar to the LMR RTK family, STYK1 has a truncated extracellular domain, but also displays a relatively short intracellular tail beyond the split kinase domain. STYK1 (also known as [N]{.ul}ovel [O]{.ul}ncogene with [K]{.ul}inase‐domain, NOK) has been suggested to co‐localize with activated EGF receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/22516751?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2229>Common abbreviationSTYK1HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18889](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18889), <http://www.uniprot.org/uniprot/Q6J9G0>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)

Comments {#bph14751-sec-128}
--------

As yet, no selective inhibitors of STYK1 have been described.

Further reading on Receptor tyrosine kinases (RTKs) {#bph14751-sec-129}
---------------------------------------------------
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=303> {#bph14751-sec-130}
===========================================================================

Overview {#bph14751-sec-131}
--------

Receptor serine/threonine kinases (RTSK), [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.7.11.30](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.7.11.30), respond to particular cytokines, the transforming growth factor β (TGFβ) and bone morphogenetic protein (BMP) families, and may be divided into two subfamilies on the basis of structural similarities. Agonist binding initiates formation of a cell‐surface complex of type I and type II RSTK, possibly heterotetrameric, where where both subunits express serine/threonine kinase activity. The type I receptor serine/threonine kinases are also known as activin receptors or activin receptor‐like kinases, ALKs, for which a systematic nomenclature has been proposed (ALK1‐7). The type II protein phosphorylates the kinase domain of the type I partner (sometimes referred to as the signal propagating subunit), causing displacement of the protein partners, such as the FKBP12 FK506‐binding protein [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3711](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3711) (<http://www.uniprot.org/uniprot/P62942>) and allowing the binding and phosphorylation of particular members of the Smad family. These migrate to the nucleus and act as complexes to regulate gene transcription. Type III receptors, sometimes called co‐receptors or accessory proteins, regulate the signalling of the receptor complex, in either enhancing (for example, presenting the ligand to the receptor) or inhibitory manners. TGFβ family ligand signalling may be inhibited by endogenous proteins, such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4933> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3971](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3971), <http://www.uniprot.org/uniprot/P19883>), which binds and neutralizes activins to prevent activation of the target receptors.

Endogenous agonists, approximately 30 in man, are often described as paracrine messengers acting close to the source of production. They are characterized by six conserved cysteine residues and are divided into two subfamilies on the basis of sequence comparison and signalling pathways activated, the TGFβ/activin/nodal subfamily and the BMP/GDF (growth/differentiation factor)/MIS (Müllerian inhibiting substance) subfamily. Ligands active at RSTKs appear to be generated as large precursors which undergo complexmaturation processes \[<http://www.ncbi.nlm.nih.gov/pubmed/18692464?dopt=AbstractPlus>\]. Some are known to form disulphide‐linked homo‐ and/or heterodimeric complexes. Thus, inhibins are α subunits linked to a variety of β chains, while activins are combinations of β subunits.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=318> {#bph14751-sec-132}
===========================================================================

Overview {#bph14751-sec-133}
--------

The type I receptor serine/threonine kinases are also known as activin receptors or activin receptor‐like kinases, ALKs, for which a systematic nomenclature has been proposed (ALK1‐7).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1784><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1785><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1786><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1787><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1789><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1790>Common abbreviationALK1ALK2BMPR1AALK4TGFBR1BMPR1BALK7HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:175](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:175), <http://www.uniprot.org/uniprot/P37023>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:171](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:171), <http://www.uniprot.org/uniprot/Q04771>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1076](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1076), <http://www.uniprot.org/uniprot/P36894>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:172](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:172), <http://www.uniprot.org/uniprot/P36896>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11772](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11772), <http://www.uniprot.org/uniprot/P36897>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1077](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1077), <http://www.uniprot.org/uniprot/O00238>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18123](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18123), <http://www.uniprot.org/uniprot/Q8NER5>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8121> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/23639540?dopt=AbstractPlus>\]----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8075> (p*K* ~i~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/18413796?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8194> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/16539403?dopt=AbstractPlus>\]----Selective inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8107> (pIC~50~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/24786585?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8107> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/24786585?dopt=AbstractPlus>\]----

Further reading on Type I receptor serine/threonine kinases {#bph14751-sec-134}
-----------------------------------------------------------

Batlle E *et al*. (2019) Transforming Growth Factor‐β Signaling in Immunity and Cancer *Immunity* **50**: 924--940

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=319> {#bph14751-sec-135}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1791><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1792><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1793><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1794><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1795>Common abbreviationActR2ActR2BMISR2BMPR2TGFBR2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:173](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:173), <http://www.uniprot.org/uniprot/P27037>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:174](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:174), <http://www.uniprot.org/uniprot/Q13705>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:465](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:465), <http://www.uniprot.org/uniprot/Q16671>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1078](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1078), <http://www.uniprot.org/uniprot/Q13873>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11773](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11773), <http://www.uniprot.org/uniprot/P37173>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.30)Antibodies--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8086> (Binding) (p*K* ~d~ 11.8) \[[10](#bph14751-bib-0010){ref-type="ref"}\]------

Further reading on Type II receptor serine/threonine kinases {#bph14751-sec-136}
------------------------------------------------------------

Batlle E *et al*. (2019) Transforming Growth Factor‐β Signaling in Immunity and Cancer *Immunity* **50**: 924‐940

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=798> {#bph14751-sec-137}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1796>Common abbreviationTGFBR3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11774](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11774), <http://www.uniprot.org/uniprot/Q03167>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=797> {#bph14751-sec-138}
===========================================================================

Overview {#bph14751-sec-139}
--------

For the receptors listed below, the exact combination of subunits forming the functional heteromeric receptors is unknown.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2585>\><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2586>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1796> (Type III), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1795> (Type II)\><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1789> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1792> (Type II), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1791> (Type II), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1784> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1785> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1786> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1794> (Type II)CouplingSmad2, Smad3 \[<http://www.ncbi.nlm.nih.gov/pubmed/19855013?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12809600?dopt=AbstractPlus>\]\>Smad1, Smad5, Smad8 \[<http://www.ncbi.nlm.nih.gov/pubmed/19855013?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12809600?dopt=AbstractPlus>\]Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5060> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11766](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11766), <http://www.uniprot.org/uniprot/P01137>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5061> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11768](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11768), <http://www.uniprot.org/uniprot/P61812>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5062> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11769](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11769), <http://www.uniprot.org/uniprot/P10600>)\><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4875> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20869](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20869), <http://www.uniprot.org/uniprot/O95393>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4881> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1069](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1069), <http://www.uniprot.org/uniprot/P12643>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4883> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1071](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1071), <http://www.uniprot.org/uniprot/P12644>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4884> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1072](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1072), <http://www.uniprot.org/uniprot/P22003>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4885> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1073](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1073), <http://www.uniprot.org/uniprot/P22004>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4886> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1074](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1074), <http://www.uniprot.org/uniprot/P18075>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4887> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21650](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21650), <http://www.uniprot.org/uniprot/Q7Z5Y6>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4888> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1075](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1075), <http://www.uniprot.org/uniprot/P34820>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4889> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4217](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4217), <http://www.uniprot.org/uniprot/Q9UK05>)

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2587><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2588><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2589>Subunits<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1789> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1792> (Type II), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1791> (Type II), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1790> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1786> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1787> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1794> (Type II)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1792> (Type II), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1791> (Type II), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1790> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1787> (Type I)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1793> (Type II), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1789> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1785> (Type I), <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1786> (Type I)CouplingSmad1, Smad5, Smad8 \[<http://www.ncbi.nlm.nih.gov/pubmed/19855013?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12809600?dopt=AbstractPlus>\]Smad2, Smad3 \[<http://www.ncbi.nlm.nih.gov/pubmed/12809600?dopt=AbstractPlus>\]Smad1, Smad5, Smad8 \[<http://www.ncbi.nlm.nih.gov/pubmed/19855013?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12809600?dopt=AbstractPlus>\]Endogenous agonists<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4936> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4214](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4214), <http://www.uniprot.org/uniprot/P27539>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4937> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4215](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4215), <http://www.uniprot.org/uniprot/P55107>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4938> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4218](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4218), <http://www.uniprot.org/uniprot/Q9NR23>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4877> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4222](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4222), <http://www.uniprot.org/uniprot/Q7Z4P5>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4939> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4224](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4224), <http://www.uniprot.org/uniprot/O60383>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4857> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6066](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6066), <http://www.uniprot.org/uniprot/P08476>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4858> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6066](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6066) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6067](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6067), <http://www.uniprot.org/uniprot/P08476> <http://www.uniprot.org/uniprot/P09529>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4859> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6067](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6067), <http://www.uniprot.org/uniprot/P09529>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5010> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6065](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6065) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6066](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6066), <http://www.uniprot.org/uniprot/P05111> <http://www.uniprot.org/uniprot/P08476>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6686> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:464](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:464), <http://www.uniprot.org/uniprot/P03971>)Comments--Activin receptors are heteromeric complexes comprising activin receptor type I and type II subunits.--

Further reading on RSTK functional heteromers {#bph14751-sec-140}
---------------------------------------------

Batlle E *et al*. (2019) Transforming Growth Factor‐β Signaling in Immunity and Cancer *Immunity* **50**: 924‐940

Comments on Receptor serine/threonine kinase (RSTK) family {#bph14751-sec-141}
----------------------------------------------------------

A number of endogenous inhibitory ligands have been identified for RSTKs, including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4882> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1070](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1070), <http://www.uniprot.org/uniprot/P12645>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5005> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6065](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6065), <http://www.uniprot.org/uniprot/P05111>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5008> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6068](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6068), <http://www.uniprot.org/uniprot/P55103>) and inhibin <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5009> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24029](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24029), <http://www.uniprot.org/uniprot/P58166>).

An appraisal of small molecule inhibitors of TGFβ and BMP signalling concluded that TGFβ pathway inhibitors were more selective than BMP signalling inhibitors \[<http://www.ncbi.nlm.nih.gov/pubmed/21740966?dopt=AbstractPlus>\]. The authors confirmed the selectivity of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6049> to inhibit TGFβ signalling through ALK4, ALK5, ALK7 \[<http://www.ncbi.nlm.nih.gov/pubmed/14978253?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4907> inhibits BMP signalling through ALK2 and ALK3, it also inhibits AMP kinase \[<http://www.ncbi.nlm.nih.gov/pubmed/11602624?dopt=AbstractPlus>\].

**Smads** were identified as mammalian orthologues of Drosophila genes termed "mothers against decapentaplegic" and may be divided into Receptor‐regulated Smads (R‐Smads, including Smad1, Smad2, Smad3, Smad5 and Smad8), Co‐mediated Smad (Co‐Smad, Smad4) and Inhibitory Smads (I‐Smad, Smad6 and Smad7). R‐Smads form heteromeric complexes with Co‐Smad. I‐Smads compete for binding of R‐Smad with both receptors and Co‐Smad.

**[Nomenclature]{.ul}[HGNC gene symbol]{.ul}[Uniprot ID]{.ul}[Other names]{.ul}**Smad1[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6767](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6767)<http://www.uniprot.org/uniprot/Q15797>JV4‐1, MADH1, MADR1Smad2[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6768](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6768)<http://www.uniprot.org/uniprot/Q15796>JV18‐1, MADH2, MADR2Smad3[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6769](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6769)<http://www.uniprot.org/uniprot/P84022>HsT17436, JV15‐2, MADH3Smad4[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6770](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6770)<http://www.uniprot.org/uniprot/Q13485>DPC4, MADH4Smad5[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6771](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6771)<http://www.uniprot.org/uniprot/Q99717>Dwfc, JV5‐1, MADH5Smad6[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6772](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6772)<http://www.uniprot.org/uniprot/O43541>HsT17432, MADH6, MADH7Smad7[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6773](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6773)<http://www.uniprot.org/uniprot/O15105>MADH7, MADH8Smad8[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6774](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6774)<http://www.uniprot.org/uniprot/O15198>MADH6, MADH9

Further reading on Receptor serine/threonine kinase (RSTK) family {#bph14751-sec-142}
-----------------------------------------------------------------

Budi EH *et al*. (2017) Transforming Growth Factor‐β Receptors and Smads: Regulatory Complexity and Functional Versatility. *Trends Cell Biol*. **27**: 658‐672 \[<https://www.ncbi.nlm.nih.gov/pubmed/28552280?dopt=AbstractPlus>\]

Chen W *et al*. (2016) Immunoregulation by members of the TGFβ superfamily. *Nat. Rev. Immunol*. **16**: 723‐740 \[<https://www.ncbi.nlm.nih.gov/pubmed/27885276?dopt=AbstractPlus>\]

Heger J *et al*. (2016) Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure. *Br. J. Pharmacol*. **173**: 3‐14 \[<https://www.ncbi.nlm.nih.gov/pubmed/26431212?dopt=AbstractPlus>\]

Luo JY *et al*. (2015) Regulators and effectors of bone morphogenetic protein signalling in the cardiovascular system. *J. Physiol. (Lond.)* **593**: 2995‐3011 \[<https://www.ncbi.nlm.nih.gov/pubmed/25952563?dopt=AbstractPlus>\]

Macias MJ *et al*. (2015) Structural determinants of Smad function in TGF‐β signaling. *Trends Biochem. Sci*. **40**: 296‐308 \[<https://www.ncbi.nlm.nih.gov/pubmed/25935112?dopt=AbstractPlus>\]

Morrell NW *et al*. (2016) Targeting BMP signalling in cardiovascular disease and anaemia. *Nat Rev Cardiol* **13**: 106‐20 \[<https://www.ncbi.nlm.nih.gov/pubmed/26461965?dopt=AbstractPlus>\]

Neuzillet C *et al*. (2015) Targeting the TGFβ pathway for cancer therapy. *Pharmacol. Ther*. **147**: 22‐31 \[<https://www.ncbi.nlm.nih.gov/pubmed/25444759?dopt=AbstractPlus>\]

van der Kraan PM. (2017) The changing role of TGFβ in healthy, ageing and osteoarthritic joints. *Nat Rev Rheumatol* **13**: 155‐163 \[<https://www.ncbi.nlm.nih.gov/pubmed/28148919?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=333> {#bph14751-sec-143}
===========================================================================

Overview {#bph14751-sec-144}
--------

Receptor tyrosine phosphatases (RTP) are cell‐surface proteins with a single TM region and intracellular phosphotyrosine phosphatase activity. Many family members exhibit constitutive activity in heterologous expression, dephosphorylating intracellular targets such as Src tyrosine kinase ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11283](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11283)) to activate signalling cascades. Family members bind components of the extracellular matrix or cell‐surface proteins indicating a role in intercellular communication.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1850><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1851><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1852><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1853><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1854><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1855><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1856>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9664](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9664), <http://www.uniprot.org/uniprot/P18433>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9665](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9665), <http://www.uniprot.org/uniprot/P23467>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9666](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9666), <http://www.uniprot.org/uniprot/P08575>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9668](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9668), <http://www.uniprot.org/uniprot/P23468>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9669](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9669), <http://www.uniprot.org/uniprot/P23469>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9670](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9670), <http://www.uniprot.org/uniprot/P10586>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9671](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9671), <http://www.uniprot.org/uniprot/P23470>Putative endogenous ligands----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6603> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6561](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6561), <http://www.uniprot.org/uniprot/P09382>) \[<http://www.ncbi.nlm.nih.gov/pubmed/10369126?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6607> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:25042](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:25042), <http://www.uniprot.org/uniprot/Q9NT99>) \[<http://www.ncbi.nlm.nih.gov/pubmed/20139422?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6607> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:25042](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:25042), <http://www.uniprot.org/uniprot/Q9NT99>) \[<http://www.ncbi.nlm.nih.gov/pubmed/20139422?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6609> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2173](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2173), <http://www.uniprot.org/uniprot/Q9P232>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6612> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2174](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2174), <http://www.uniprot.org/uniprot/Q8IWV2>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6613> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2175](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2175), <http://www.uniprot.org/uniprot/O94779>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6614> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2176](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2176), <http://www.uniprot.org/uniprot/Q9UQ52>) \[<http://www.ncbi.nlm.nih.gov/pubmed/20133774?dopt=AbstractPlus>\]Inhibitors----------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8770> (pIC~50~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/18579388?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8831> (p*K* ~i~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/21882820?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1857><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1858><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1859><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1860><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1861><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1862><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1863>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9672](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9672), <http://www.uniprot.org/uniprot/Q9HD43>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9673](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9673), <http://www.uniprot.org/uniprot/Q12913>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9674](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9674), <http://www.uniprot.org/uniprot/Q15262>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9675](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9675), <http://www.uniprot.org/uniprot/P28827>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9676](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9676), <http://www.uniprot.org/uniprot/Q16849>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9677](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9677), <http://www.uniprot.org/uniprot/Q92932>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9678](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9678), <http://www.uniprot.org/uniprot/Q16827>Putative endogenous ligands----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6619> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6563](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6563), <http://www.uniprot.org/uniprot/P17931>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6615> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6564](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6564), <http://www.uniprot.org/uniprot/Q08380>) \[<http://www.ncbi.nlm.nih.gov/pubmed/21094132?dopt=AbstractPlus>\]--------Inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8856> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/23713581?dopt=AbstractPlus>\]------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1864><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1865><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1866><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1867><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1868><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1869>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9679](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9679), <http://www.uniprot.org/uniprot/Q9UMZ3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9680](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9680), <http://www.uniprot.org/uniprot/Q15256>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9681](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9681), <http://www.uniprot.org/uniprot/Q13332>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9682](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9682), <http://www.uniprot.org/uniprot/O14522>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9683](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9683), <http://www.uniprot.org/uniprot/Q92729>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9685](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9685), <http://www.uniprot.org/uniprot/P23471>Putative endogenous ligands----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6616> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2465](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2465), <http://www.uniprot.org/uniprot/O14594>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6607> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:25042](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:25042), <http://www.uniprot.org/uniprot/Q9NT99>) \[<http://www.ncbi.nlm.nih.gov/pubmed/20139422?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19833921?dopt=AbstractPlus>\]----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6617> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2171](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2171), <http://www.uniprot.org/uniprot/Q12860>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6618> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9630](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9630), <http://www.uniprot.org/uniprot/C9JR52>) (acts as a negative regulator) \[<http://www.ncbi.nlm.nih.gov/pubmed/20133774?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10706604?dopt=AbstractPlus>\]Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8850> (pIC~50~ 5.4) \[[78](#bph14751-bib-0078){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10109> (pIC~50~ 4.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/9276730?dopt=AbstractPlus>\]------

Further reading on Receptor tyrosine phosphatase (RTP) family {#bph14751-sec-145}
-------------------------------------------------------------

Papadimitriou E *et al*. (2016) Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as regulators of angiogenesis and cancer. *Biochim. Biophys. Acta* **1866**: 252‐265 \[<https://www.ncbi.nlm.nih.gov/pubmed/27693125?dopt=AbstractPlus>\]

Stanford SM *et al*. (2017) Targeting Tyrosine Phosphatases: Time to End the Stigma. *Trends Pharmacol. Sci*. **38**: 524‐540 \[<https://www.ncbi.nlm.nih.gov/pubmed/28412041?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=334> {#bph14751-sec-146}
===========================================================================

Overview {#bph14751-sec-147}
--------

Dysregulated TNFR signalling is associated with many inflammatory disorders, including some forms of arthritis and inflammatory bowel disease, and targeting TNF has been an effective therapeutic strategy in these diseases and for cancer immunotherapy \[<http://www.ncbi.nlm.nih.gov/pubmed/23840967?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26008591?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25169849?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1871><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1872><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1873><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1875><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2322>Systematic nomenclatureTNFRSF1ATNFRSF1BTNFRSF3TNFRSF4TNFRSF5TNFRSF6TNFRSF6BCommon abbreviationTNFR1TNFR2----------HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11916](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11916), <http://www.uniprot.org/uniprot/P19438>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11917](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11917), <http://www.uniprot.org/uniprot/P20333>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6718](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6718), <http://www.uniprot.org/uniprot/P36941>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11918](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11918), <http://www.uniprot.org/uniprot/P43489><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874>, <http://www.uniprot.org/uniprot/P25942><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1875>, <http://www.uniprot.org/uniprot/P25445>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11921](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11921), <http://www.uniprot.org/uniprot/O95407>Adaptor proteinsTRADDTRAF1, TRAF2, TRAF5TRAF3, TRAF4, TRAF5TRAF1, TRAF2, TRAF3, TRAF5TRAF1, TRAF2, TRAF3, TRAF5, TRAF6FADD--Endogenous ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5064> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6709](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6709), <http://www.uniprot.org/uniprot/P01374>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5073> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11892](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11892), <http://www.uniprot.org/uniprot/P01375>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5074> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11892](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11892), <http://www.uniprot.org/uniprot/P01375>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5064> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6709](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6709), <http://www.uniprot.org/uniprot/P01374>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5073> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11892](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11892), <http://www.uniprot.org/uniprot/P01375>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5070> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11930](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11930), <http://www.uniprot.org/uniprot/O43557>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6142> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6142> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6709](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6709) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6711](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6711), <http://www.uniprot.org/uniprot/P01374> <http://www.uniprot.org/uniprot/Q06643>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5076> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11934](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11934), <http://www.uniprot.org/uniprot/P23510>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5077> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11935](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11935), <http://www.uniprot.org/uniprot/P29965>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5078> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11936](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11936), <http://www.uniprot.org/uniprot/P48023>)--Ligands------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9092> (Binding) (pIC~50~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/24930776?dopt=AbstractPlus>\]------Comments------The OX40/OX40L pair is involved in late T‐cell costimulatory signaling and both are transiently expressed following antigen recognition, and blocking OX40/OX40L is reported to prevent the development of disease in *in vivo* autoimmune and inflammatory disease models \[<http://www.ncbi.nlm.nih.gov/pubmed/26215166?dopt=AbstractPlus>\]----Decoy receptor for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5070> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11930](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11930), <http://www.uniprot.org/uniprot/O43557>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5071> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11931](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11931), <http://www.uniprot.org/uniprot/O95150>) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5078> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11936](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11936), <http://www.uniprot.org/uniprot/P48023>).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1876><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1877><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1878><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1879><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1880><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2323><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2324>Systematic nomenclatureTNFRSF7TNFRSF8TNFRSF9TNFRSF10ATNFRSF10BTNFRSF10CTNFRSF10DCommon abbreviation------DR4DR5----HGNC, UniProt<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1876>, <http://www.uniprot.org/uniprot/P26842>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11923](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11923), <http://www.uniprot.org/uniprot/P28908>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11924](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11924), <http://www.uniprot.org/uniprot/Q07011>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11904](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11904), <http://www.uniprot.org/uniprot/O00220>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11905](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11905), <http://www.uniprot.org/uniprot/O14763>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11906](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11906), <http://www.uniprot.org/uniprot/O14798>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11907](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11907), <http://www.uniprot.org/uniprot/Q9UBN6>Adaptor proteinsTRAF2, SIVATRAF1, TRAF2, TRAF3, TRAF5TRAF1, TRAF2, TRAF3FADDFADD----Endogenous ligands[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11937](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11937) ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11937](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11937), <http://www.uniprot.org/uniprot/P32970>)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1877> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11938](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11938), <http://www.uniprot.org/uniprot/P32971>)<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1878> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11939](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11939), <http://www.uniprot.org/uniprot/P41273>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5065> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11925](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11925), <http://www.uniprot.org/uniprot/P50591>)------Endogenous agonists--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5065> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11925](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11925), <http://www.uniprot.org/uniprot/P50591>) \[[251](#bph14751-bib-0251){ref-type="ref"}\]----Agonists------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8889> \[[81](#bph14751-bib-0081){ref-type="ref"}\]------Antibodies--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6772> (Inhibition)----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9334> (Agonist) (p*K* ~d~ \~8.5) \[[251](#bph14751-bib-0251){ref-type="ref"}\]----Comments----------Decoy receptor for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5065> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11925](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11925), <http://www.uniprot.org/uniprot/P50591>).Decoy receptor for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5065> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11925](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11925), <http://www.uniprot.org/uniprot/P50591>).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1881><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1882><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1883><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1884><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1885><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1886><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1887>Systematic nomenclatureTNFRSF11ATNFRSF11BTNFRSF25TNFRSF12ATNFRSF13BTNFRSF13CTNFRSF14Common abbreviationRANKOPGDR3----BAFF‐RHVEMHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11908](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11908), <http://www.uniprot.org/uniprot/Q9Y6Q6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11909](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11909), <http://www.uniprot.org/uniprot/O00300>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11910](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11910), <http://www.uniprot.org/uniprot/Q93038>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18152](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18152), <http://www.uniprot.org/uniprot/Q9NP84>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18153](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18153), <http://www.uniprot.org/uniprot/O14836>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17755](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17755), <http://www.uniprot.org/uniprot/Q96RJ3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11912](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11912), <http://www.uniprot.org/uniprot/Q92956>Adaptor proteinsTRAF1, TRAF2, TRAF3, TRAF5, TRAF6--TRADDTRAF1, TRAF2, TRAF3TRAF2, TRAF5, TRAF6TRAF3TRAF2, TRAF3, TRAF5Endogenous ligands<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5066> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11926](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11926), <http://www.uniprot.org/uniprot/O14788>)--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5071> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11931](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11931), <http://www.uniprot.org/uniprot/O95150>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5067> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11927](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11927), <http://www.uniprot.org/uniprot/O43508>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5068> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11928](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11928), <http://www.uniprot.org/uniprot/O75888>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5069> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11929](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11929), <http://www.uniprot.org/uniprot/Q9Y275>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5069> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11929](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11929), <http://www.uniprot.org/uniprot/Q9Y275>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4891> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21087](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21087), <http://www.uniprot.org/uniprot/Q7Z6A9>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5070> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11930](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11930), <http://www.uniprot.org/uniprot/O43557>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5064> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6709](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6709), <http://www.uniprot.org/uniprot/P01374>)Comments--Acts as a decoy receptor for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5066> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11926](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11926), <http://www.uniprot.org/uniprot/O14788>) and possibly for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5065> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11925](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11925), <http://www.uniprot.org/uniprot/P50591>).The only known TNFSF ligand for DR3 is TNF‐like protein 1A (TL1A) \[<http://www.ncbi.nlm.nih.gov/pubmed/22612445?dopt=AbstractPlus>\].--------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1889><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1890><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1891><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1892><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1893>Systematic nomenclatureTNFRSF16TNFRSF17TNFRSF18TNFRSF19TNFRSF19LTNFRSF21Common abbreviation--BCMAGITRTAJ--DR6HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7809](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7809), <http://www.uniprot.org/uniprot/P08138>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11913](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11913), <http://www.uniprot.org/uniprot/Q02223>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11914](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11914), <http://www.uniprot.org/uniprot/Q9Y5U5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11915](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11915), <http://www.uniprot.org/uniprot/Q9NS68><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1892>, <http://www.uniprot.org/uniprot/Q969Z4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13469](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13469), <http://www.uniprot.org/uniprot/O75509>Adaptor proteinsTRAF2, TRAF4, TRAF6TRAF1, TRAF2, TRAF3, TRAF5, TRAF6TRAF1, TRAF2, TRAF3, SIVATRAF1, TRAF2, TRAF3, TRAF5TRAF1TRADDEndogenous ligands[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7808](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7808) ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7808](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7808), <http://www.uniprot.org/uniprot/P01138>) (pIC~50~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/22227462?dopt=AbstractPlus>\], [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1033](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1033) ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1033](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1033), <http://www.uniprot.org/uniprot/P23560>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5033> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8023](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8023), <http://www.uniprot.org/uniprot/P20783>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5034> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8024](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8024), <http://www.uniprot.org/uniprot/P34130>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5068> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11928](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11928), <http://www.uniprot.org/uniprot/O75888>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5069> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11929](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11929), <http://www.uniprot.org/uniprot/Q9Y275>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5072> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11932](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11932), <http://www.uniprot.org/uniprot/Q9UNG2>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5064> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6709](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6709), <http://www.uniprot.org/uniprot/P01374>)----CommentsOne of the two receptor types for the neurotrophins (factors that stimulate neuronal cell survival and differentiation). The other family of neurotrophin receptors are the Trk family of receptor tyrosine kinases.----Believed to be essential during embryonic development.Abundant in hematologic tissues. Selective receptor for TNF receptor‐associated factor 1 (TRAF1). Activates the NF‐κB pathway.--

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1894><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1895><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1896><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2325>Systematic nomenclature----TNFRS27--HGNC, UniProt----[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17756](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17756), <http://www.uniprot.org/uniprot/Q9HAV5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2895](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2895), <http://www.uniprot.org/uniprot/Q9UNE0>Adaptor proteins----TRAF1, TRAF3, TRAF6TRAF1, TRAF2, TRAF3Endogenous ligands----<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1896> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3157](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3157), <http://www.uniprot.org/uniprot/Q92838>) \[<http://www.ncbi.nlm.nih.gov/pubmed/11039935?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2325> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3157](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3157), <http://www.uniprot.org/uniprot/Q92838>) \[<http://www.ncbi.nlm.nih.gov/pubmed/11039935?dopt=AbstractPlus>\]CommentsOnly identified in mouse to date. A potential decoy receptor for the cytotoxic ligand TNFSF10/TRAIL. Does not contain a cytoplasmic death domain so does not induce apoptosis, and does not activate the NF‐κB signalling pathway.Only identified in mouse to date. A potential decoy receptor for the cytotoxic ligand TNFSF10/TRAIL. Does not contain a cytoplasmic death domain so does not induce apoptosis, and does not activate the NF‐κB signalling pathway.Receptor for the EDA‐A2 isoform of ectodysplasin encoded by the anhidrotic ectodermal dysplasia (*EDA*) gene.Cell surface receptor for ectodysplasin A (a morphogen involved in the development of ectodermal tissues, including skin, hair, nails, teeth, and sweat glands).

Comments {#bph14751-sec-148}
--------

TNFRSF1A is preferentially activated by the shed form of TNF ligand, whereas the membrane‐bound form of TNF serves to activate TNFRSF1A and TNFRSF1B equally. The neurotrophins nerve growth factor ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7808](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7808) ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7808](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7808), <http://www.uniprot.org/uniprot/P01138>)), brain‐derived neurotrophic factor ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1033](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1033) ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1033](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1033), <http://www.uniprot.org/uniprot/P23560>)), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5033> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8023](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8023), <http://www.uniprot.org/uniprot/P20783>) ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8023](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8023)) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5034> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8024](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8024), <http://www.uniprot.org/uniprot/P34130>) (NTF4) are structurally unrelated to the TNF ligand superfamily but exert some of their actions through the "low affinity nerve growth factor receptor" (NGFR (TNFRSF16)) as well as through the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304#show_overview_326> of receptor tyrosine kinases. The endogenous ligands for EDAR and EDA2R are, respectively, the membrane (<http://www.uniprot.org/uniprot/Q92838#PRO_0000034538>) and secreted (<http://www.uniprot.org/uniprot/Q92838#PRO_0000034539>) isoforms of Ectodysplasin‐A (EDA, <http://www.uniprot.org/uniprot/Q92838>).
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